University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
Fall 2011

Innate Signals in the Macrophage Determine the Severity of
Toxoplasma Gondii infection
Ryan J. Whitmarsh
ryanjw@mail.med.upenn.edu

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Immunology of Infectious Disease Commons, Immunopathology Commons, Other
Immunology and Infectious Disease Commons, and the Parasitology Commons

Recommended Citation
Whitmarsh, Ryan J., "Innate Signals in the Macrophage Determine the Severity of Toxoplasma Gondii
infection" (2011). Publicly Accessible Penn Dissertations. 433.
https://repository.upenn.edu/edissertations/433

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/433
For more information, please contact repository@pobox.upenn.edu.

Innate Signals in the Macrophage Determine the Severity of Toxoplasma Gondii
infection
Abstract
Toxoplasma gondii is an obligate intracellular pathogen that is a cause of significant morbidity and
mortality in humans and animals. The immune response necessary to control this infection requires
successful coordination of strong innate and adaptive responses. Recognition of the pathogen by innate
accessory cells such as macrophages, neutrophils, and dendritic cells induces the release of IL-12 that
activates NK and T cells to produce protective IFN-g, the major mediator of immunity to T. gondii. T. gondii
has many mechanisms to limit the activation of innate cells and to reduce the production of IL-12. One of
the ways T. gondii achieves this is by inducing the phosphorylation of the transcription factor Signal
Transducer of Activation 3 (STAT3) that leads to repressed pro-inflammatory responses such as
diminished IL-12 production. How STAT3 antagonizes inflammatory responses is poorly understood but
the Suppressors of Cytokine Signaling (SOCS) proteins are downstream candidate molecules that
antagonize cytokine signaling. Recent studies have identified SOCS proteins as being important during
infection with a number of pathogens and have provided insights into how intracellular pathogens affect
STAT signaling to promote their replication and survival. In particular, SOCS1 is thought to inhibit IFN-g
signals whereas SOCS3 antagonizes IL-6 signals. Studies have shown that both of these proteins are
upregulated in other models but little is known about how they contribute to the outcome of infection.
This thesis provides evidence that the IL-6 signaling in macrophages reduces the cell’s ability to produce
IL-12 that is enhanced in the absence of SOCS3. Furthermore, infection of SOCS3 conditional knockouts
leads to acute susceptibility with high parasite burdens associated with impaired IL-12 production.
Blocking anti-bodies to IL-6 as well as addition of exogenous IL-12 rescues the lethality in these mice
suggesting that IL-6 is a natural antagonist of IL-12 production during infection with T. gondii. This thesis
will discuss the roles that IL-6, STAT3, and SOCS3 play during infection with T. gondii and how these
molecules affect cytokine regulation, cellular recruitment, and microbicidal activity and also how these
studies enhance our understanding of inflammation and resistance to infection.
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Abstract
Innate signals in the macrophage determine the severity of Toxoplasma
gondii infection

Ryan J. Whitmarsh

Christopher A. Hunter

Toxoplasma gondii is an obligate intracellular pathogen that is a cause of significant
morbidity and mortality in humans and animals. The immune response necessary to
control this infection requires successful coordination of strong innate and adaptive
responses. Recognition of the pathogen by innate accessory cells such as macrophages,
neutrophils, and dendritic cells induces the release of IL-12 that activates NK and T cells
to produce protective IFN-γ, the major mediator of immunity to T. gondii. T. gondii has
many mechanisms to limit the activation of innate cells and to reduce the production of
IL-12. One of the ways T. gondii achieves this is by inducing the phosphorylation of the
transcription factor Signal Transducer of Activation 3 (STAT3) that leads to repressed
pro-inflammatory responses such as diminished IL-12 production. How STAT3
antagonizes inflammatory responses is poorly understood but the Suppressors of
Cytokine Signaling (SOCS) proteins are downstream candidate molecules that antagonize
cytokine signaling. Recent studies have identified SOCS proteins as being important
during infection with a number of pathogens and have provided insights into how
iii

intracellular pathogens affect STAT signaling to promote their replication and survival.
In particular, SOCS1 is thought to inhibit IFN-γ signals whereas SOCS3 antagonizes IL-6
signals. Studies have shown that both of these proteins are upregulated in other models
but little is known about how they contribute to the outcome of infection. This thesis
provides evidence that the IL-6 signaling in macrophages reduces the cell’s ability to
produce IL-12 that is enhanced in the absence of SOCS3. Furthermore, infection of
SOCS3 conditional knockouts leads to acute susceptibility with high parasite burdens
associated with impaired IL-12 production. Blocking anti-bodies to IL-6 as well as
addition of exogenous IL-12 rescues the lethality in these mice suggesting that IL-6 is a
natural antagonist of IL-12 production during infection with T. gondii. This thesis will
discuss the roles that IL-6, STAT3, and SOCS3 play during infection with T. gondii and
how these molecules affect cytokine regulation, cellular recruitment, and microbicidal
activity and also how these studies enhance our understanding of inflammation and
resistance to infection.
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I.

Literature Review

1

Introduction
Toxoplasma gondii is an opportunistic pathogen of patients with a variety of
primary and secondary deficiencies in T cell function and also is an important cause of
disease in livestock 1-3. This parasite was first identified in the early part of the 20th
century as a parasite of rodents, but was subsequently linked to human disease as an
opportunistic infection of immune-compromised patients, developing fetuses, and
patients with Acquired Immunodeficiency Syndrome (AIDS) whose T cell numbers have
fallen to critically low levels to allow reactivation of the parasite 4-7. Other immunecompromised individuals that have T cell defects are also susceptible to primary and
reactivated toxoplasmosis and these patients illustrate the critical role for T cell-mediated
immune responses in controlling this infection 8-11.
Given its ability to be easily sustained in tissue culture, infect mice, and be
genetically engineered, T. gondii has become a useful laboratory tool for researching the
molecular genetics of parasites, immunology, and host-pathogen interactions. In addition,
T. gondii provides a robust model of an intracellular pathogen that requires strong Th1mediated immunity for control. Thus, basic studies using T. gondii have helped define the
importance of cytokines such as IL-12 and IFN-γ in the killing and clearance of
intracellular pathogens by mechanisms including but not limited to oxygen radicals,
GTPase colocalization, autophagy, and proteasomal degradation 12-21. Analysis of
immunity to T. gondii has also increased our understanding of the role of cytokines such
as IL-6, IL-10, TGF-β, and IL-27 in limiting inflammation 22-27. IL-6 has many functions
in Th17, Treg, and neutrophil biology and historically has been associated with pro2

inflammatory responses and is required for chronic resistance to T. gondii. As a result of
this work, IL-6 has emerged as an important regulatory cytokine that can inhibit acute
inflammatory responses from macrophages and will be the subject of much of Chapters II
and III of this thesis.
This thesis will address the role of macrophage-mediated killing and clearance of
T. gondii and the signals that regulate this process. Chapter I will provide a broad
overview of the biology of T. gondii and the immune mechanisms needed to control this
pathogen. Chapter II will focus on the signaling events that follow infection of a cell by
T. gondii and how these signals regulate survival of the parasite. Specifically, Chapter II
will describe how T. gondii induces Signal Transducer and Activator of Transcription 3
(STAT3) and will highlight how this activation limits IL-12 production. Chapter III will
introduce the relevance of IL-6 to parasite control and provide evidence that IL-6 is a
prominent inhibitor of IL-12 responses in the absence of its negative regulator,
Suppressor of Cytokine Signaling 3 (SOCS3). This section will also address how IL-6
inhibits acute immune responses and will discuss what effects the cytokine has on Th1
immunity and intracellular killing of T. gondii. Chapter IV will discuss other studies
involving the motility of T. gondii and biological aspects of the parasite that help dictate
surival and dissemination. Finally, Chapter V will conclude this thesis with a discussion
of research that has arisen from this work and address future directions suggested by this
work.
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Toxoplasma gondii
Biology
T. gondii has been studied for over 100 years and much of its biology and lifecycle are well described. T. gondii exists in several forms in its definitive host, the cat, as
well as its intermediate hosts. Cat populations are vital to transmission, however, as T.
gondii infection does not occur on isolated islands without feline populations 28. The
transmission cycle of T. gondii is described in detail in Figure 1. There is a motile,
proliferative form called the tachyzoite which allows for dissemination within the host
and there is a cystozoite form called the bradyzoite, which is located within muscle and
brain tissues and allows persistence and horizontal transmission following ingestion 28-31.
This latter process can occur through the consumption of contaminated meat or the
ingestion of oocysts from the environment 32. Oocysts are shed in the feces of wild and
domestic felids, the definitive host, and ingested by other small animals such as birds and
rodents. Once consumed, the intestinal digestive enzymes induce activation of the
sporozoite/bradyzoite into a tachyzoite that invades a cell and reproduces asexually by a
process known as endodyogeny, subsequently disseminating through the body.33, 34.

4

Adapted from the CDC, http://www.dpd.cdc.gov/dpdx/html/Toxoplasmosis.htm

Figure 1. Life cycle of T. gondii. A. Cats are the definitive host and become infected
following consumption of infected prey animals, typically rodents and birds. B. Sexual
reproduction occurs with the feline intestine and oocysts are shed fecally. C.
Intermediate hosts, i.e. warm-blooded non-feline animals, ingest oocysts from soil and
water containing excreted cysts. These cysts become activated in the stomach of hosts,
disseminate, infect new cells, and encyst in tissues like muscle and brain. D. Humans are
infected similarly by oocysts ingested from infected water, fecal-oral transmission from
contact with infected areas such as litterboxes, and undercooked meat. E. Vertical
transmission of T. gondii is possible from recently infected mothers leading to congenital
toxoplasmosis. F. An intact immune response in the host drives development of
tachyzoites into bradyzoites or the cyst form.
5

Epidemiology and Clinical Significance
T. gondii was first identified in 1907 when Nicolle and colleagues identified a
crescent-shaped parasite in rodent tissues at the Institut Pasteur in Tunis 35. Based on its
morphology, they named the parasite Toxoplasma gondii from the Latin toxo meaning arc
or bow and plasma meaning life 35. Gondii was a misspelled version of the rodent host
from which it was isolated, Ctenodactylus gundii 35. Although originally described as a
parasite of rodents and later a rabbit in Brazil 36, it was identified nearly 30 years later in
the brain of a 3 day-old newborn with encephalomyelitis 37. Following additional
confirmation of T. gondii isolates in tissues from humans presenting with various
conditions, a causal link between infection and some forms of encephalitis,
choriomeningitis, and retinitis began to emerge 37-39. T. gondii infects multiple
mammalian hosts and current estimates of seroprevalence range from 20-30% of humans
worldwide 39. As a result, T. gondii is now considered a pathogen of both clinical and
veterinary significance given its wide prevalence and the ability to cause clinical disease
in humans and animals.
T. gondii is one of the most prevalent parasitic infections in the world, recognized
as one of the leading causes of waterborne illness internationally, and accounts for
approximately 20% of the deaths related to foodborne illnesses in the United States 40.
Estimates vary, but T. gondii seroprevalence in the U.S. has been described to be between
10 and 30% while achieving rates upwards of 40-70% in countries such as France, Brazil,
and parts of Africa39, 41-45.
Although T. gondii was first identified in humans associated with clinical disease,
seroprevalence studies indicate that most chronic infections are asymptomatic in
6

immune-competent individuals. However, these cases are likely underrepresented as
symptoms such as fatigue, nausea, fever, and lymphadenopathy often go unreported.
Conversely, there have been reports of susceptible populations of healthy individuals that
develop disease, usually associated with unique strains 46. The more extreme cases may
present with myocarditis, splenomegaly, hepatitis, pneumonia and severe
lymphadenopathy 47-51. These severe clinical manifestations are rare in immunecompetent individuals but more frequent in immuno-compromised hosts such as persons
living with HIV/AIDS and fetuses 38.
Congenital transmission usually occurs following primary infection during
pregnancy although such infections do not necessarily lead to transmission 38, 39.
Previous exposure to T. gondii induces natural immunity involving T cell responses and
antibodies that make it less likely that vertical transmission will occur. There is a
correlation with the gestation time and disease severity and incidence; infections during
the 1st trimester are less common and more severe while the opposite is true for infections
occurring during the 2nd and 3rd trimesters 52. Infection in utero may result in
spontaneous abortions in humans39, 53, 54 or may manifest as fetal hydrocephaly,
splenomegaly, hepatomegaly, impaired development, altered neurological function, and
mental retardation 39, 53, 54. Although most infections are considered mild, some disease
may manifest later during life, often during puberty 38.

T. gondii and HIV
Since the advent of the HIV pandemic, T. gondii has emerged as a significant
cause of morbidity and mortality in human populations and remains one of the most
7

clinically important parasitic infections worldwide. During the early 1980’s, there was a
large increase in clinical toxoplasmosis or toxoplasmic encephalitis (TE) in patients
presenting with a novel immunodeficiency disease that resulted in loss of T cell
populations 55, 56. It was soon discovered that along with Kaposi’s Sarcoma Herpes Virus
(KSHV) and Pneumocystis carinii, T. gondii was an opportunistic pathogen in these
HIV/AIDS patients 57. It is now recognized that patients with primary or acquired
immune-deficiencies such as HIV/AIDS, certain immune cell defects such as Hyper IgM
Syndrome, immune-suppressive cancers or those undergoing suppressive chemotherapy
treatments, and transplant recipients are at risk for primary or reactivation of a latent
infection 7, 8, 10, 58, 59. Overall, disease tends to be associated with strong defects in T cell
function and therefore it is not surprising that patients with HIV/AIDS whose CD4+ T
cell counts fall below 200 cells/mm3 have difficulty controlling the parasite 5. However,
the development of highly active anti-retroviral therapy (HAART) has helped restore
immune function in HIV/AIDS patients and decreased the incidence and severity of
clinical TE 60, 61.

Parasite Morphology and Motility
T. gondii belongs to the phylum Apicomplexa and is closely related to a number of
similarly medically important parasites such as Cryptosporidium species and the malarial
parasites of the Plasmodium genus 62. These pathogens are significant causes of
morbidity worldwide and studies have identified much of the basic biology, transmission
cycle, and pathogenicity yet few have addressed how structural proteins influence hostpathogen interactions and virulence.
8

Apicomplexans contain many unusual subcellular structures and organelles
including the inner membrane complex (IMC), a series of flattened vesicles located
beneath the plasma membrane (PM), which comprises the pellicle along with the PM 63,
64

. Many proteins are associated with the pellicle and involved in parasite motility and

invasion. TgPHIL1 (Photosensitized INA-Labeled protein 1) is a highly conserved
protein among Apicomplexans but shares little homology in other phyla 63. Although
TgPHIL1 is membrane associated, TgPHIL1 extracts much like a cytoskeletal protein
suggesting that it has functions in motility and invasion. In vitro, TgPHIL1 knockout
parasites show distinct morphological differences from wild type parasites and are
outcompeted in viability assays (Barkhuff, in press). During infection, deletion of
TgPHIL1 does not enhance survival in the mice however, the parasites have a similar
rounded morphology, disseminate less quickly, and infected mice have lower parasite
burdens. This suggests that TgPHIL1 is involved in some aspect of parasite replication,
invasion, and dissemination.
Similarly to TgPHIL1, Apical membrane antigen-1 (AMA1) is a microneme
protein that is highly conserved among Apicomplexan parasites and seems to be involved
in parasite motility and invasion 64-66. AMA1 has received considerable attention as a
malaria vaccine candidate given its proposed roles in Plasmodium dissemination 67-69.
Antibodies against AMA1 inhibit invasion 66, as do phage-displayed peptides derived
directed against Plasmodium AMA1 70-72 A tetracyline-inducible deletion of a conditional
AMA1 mutant shows that AMA1-depleted parasites are impaired in their ability to attach
to host cells and to regulate rhoptry secretion, necessary for productive invasion and
immunity evasion 63.
9

Parasite Virulence
There is evidence that strain differences in T. gondii impact clinical disease.
Originally, T. gondii was described as consisting of three clonal lineages 73, but, more
recent studies have described T. gondii as being more genetically variable. In North
America and Europe, three common strains (I, II, and III) exist. These are also present in
other parts of the world such as South America and Africa, but are prevalent at a varying
frequency alongside various recombinant and novel genotypes 73. Associated with
genetic variation are differences in parasite virulence. Typically, type I strains, of which
RH is the most widely used laboratory strain, are highly virulent with a lethal dose (ld100)
of 1 sufficient to kill 100% of mice 74, 75. Type II strains, Me49 and Prugniaud (Pru) are
the most widely used laboratory strains and will be described in this thesis, are
considerably less virulent, with a reported ld50 of around 100-1000 parasites 75, 76. Type
III strains are generally considered less virulent than type II strains although this is not
necessarily true for all isolates 74. Overall, there is significant variability in the virulence
of different strains of T. gondii that, as the next section will discuss, can affect the type of
clinical disease presented by patients.
As previously noted, most human infections with T. gondii are asymptomatic and
all three clonal lineages infect humans. It has long been considered that the strain of T.
gondii could predict the type and/or severity of human disease 77, 78. Toxoplasmosis
associated with HIV/AIDS has been shown to have a strong type II bias although the
reason for this is not known 73, 77. Conversely, ocular disease has primarily been
associated with type I genotypes 79, 80. The reasons for these disease variations are
unclear, but there are numerous hypotheses for these observed differences. Type I strains
10

have been shown to replicate more quickly than type II strains in vitro but that has not
been shown to be necessarily true in vivo 77. There are also suggestions that cells infected
with type II strains migrate further than those infected with type I strains although type I
strains may cross tissue barriers in vivo more readily 81-83. Studies to determine whether
these events dictate the differences observed in virulence have been thus far been
inconclusive.
From an immune perspective, there are additional important distinguishing factors
between type I and type II strains that may affect host control. It has been shown that
type II strains elicit more protective IL-12 responses in vivo than type I 84. Since IL-12 is
required for resistance to T. gondii, this is an important observation that may indicate
differences in how these parasites interact with the innate immune system. Pru induces
stronger DC and antigen-specific CD8+ T cell responses than RH; treatment of RHinfected mice with IL-12 can restore these responses 85. This disparity in IL-12
production has recently been attributed to a the functions of a parasite kinase, ROP16 86,
87

, and while both type I and type II strains possess this kinase, the type I strain is able to

phosphorylate the transcription factor Signal Transducer and Activator of Transcription 3
(STAT3) more strongly than the type II ROP16. This enhanced STAT3 activation has
been associated with decreases in IL-12 and TNF-α production in vitro 87, 88. This
immune modulation will be discussed in more detail in a later section that details how T.
gondii influences host-cell signaling. However, it appears that multiple differences in
rates of replication, motility, and host-pathogen interactions all contribute to the outcome
of infection.
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Immunity to T. gondii
While patients with immune-deficiencies highlight the need for T cells for control
of T. gondii, the first evidence of protective immunity came as a consequence of a
diagnostic clinical test for T. gondii identified by Sabin and Feldman in 1948 39, 89. A
serologic ‘dye test’, this assay provided for rapid diagnosis from blood of the presence of
antibodies to T. gondii and allowed for advances in diagnostic epidemiology. This
included the ability to identify fetuses at risk for disease and individuals at risk for
reactivation. While early studies focused on the antibody response to T. gondii, a
powerful cell-mediated response to T. gondii was described by Frenkel in 1967 and this
provided the foundation for subsequent studies 90. The following section will describe
the current understanding of innate and adaptive responses to T. gondii and Figure 2
shows a model of the important cell types and immune molecules relevant to parasite
control.

Innate Immunity
Successful control of T. gondii requires innate responses that are important for
directing effective adaptive responses. Recognition of specific parasite proteins by
accessory cells such as macrophages, dendritic cells (DCs), natural killer (NK) cells, and
neutrophils is necessary for the innate response and functions through pattern recognition
receptors (PRRs) such as toll-like receptors (TLRs) 2 and 11 91-95. T. gondii has many
surface-bound and secreted antigens, such as cyclophillin 18 and profilin, that bind to
cellular receptors which initiate a chain of signaling events that involve Myeloid
12

Differentiation primary response gene 88 (MyD88) and nuclear factor κB (NFκB)
leading to production of TNF-α and IL-12 91, 96-99. These cytokines are important for
control; TNF-α is a potent agonist of the intracellular killing mechanisms of phagocytic
cells such as macrophages 20, 100 while IL-12 acts primarily on NK and T cells to induce
IFN-γ production 20, 100-102.
IL-12 is produced by neutrophils 103, 104, macrophages, monocytes, and DCs
following stimulation with T. gondii although some evidence suggests that conventional
DCs (CD8a+) and plasmacytoid DCs (pDCs) are the major contributors 101, 105, 106, 107-111.
IL-12 is composed of two subunits, p35 and p40, and p40-deficient mice are susceptible
to acute toxoplasmosis 103, 112. IL-12 is necessary during the first 3 days of T. gondii
infection; treatment with IL-12 can rescue p40-/- mice but not if administered after day 3
post-infection 17. During these few first few days of infection, IL-12 induces NK cells to
produce IFN-γ and become cytolytic and this initial wave of NK cell activity is thought to
delay parasite replication until an effective adaptive response can be generated 103. While
NK cells can provide some resistance to T. gondii infection 102, long-term resistance is
dependent on T cells and the IFN-γ secreted by T cells, and their cytolytic functions 15,
113

.

Adaptive Immunity
Proper activation of T cells is thought to require three signals. Major
histocombatibility complex (MHC) proteins present antigen to the cognate receptor on T
cells. MHC loading of antigens comes in two flavors: MHC Class I is expressed by most
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cells while MHC Class II is mainly expressed by professional APCS. Proteins are
sampled from both the extracellular milieu (MHC Class II) and intracellular
compartments (MHC Class I) and these are converted into short peptides. The peptides
loaded on Class I molecules are a general reflection of the repertoire of pathogen proteins
but include many self-peptides as well 114. Class II molecules are restricted to
professional APCs and often present peptides from phagocytosed microbial products. The
MHC-peptide complex then activates a T cell through its cognate T cell receptor (TCR)
and provides the first signal 115. Accessory cells that also express co-stimulatory
molecules such as CD40, CD80, and CD86 provide a second signal to T cells through
binding their cognate receptors such as CD28 116, 117. The third signal is IL-12 which
polarizes CD4+ T cells to a Th1 phenotype that produces IFN-γ and promotes the
expansion of CD8+ T cells to become IFN-γ-producing CTLs 118-121.
This requirement for T cells to mediate immunity to T. gondii was highlighted
during the 1980s, when the population of immune-compromised hosts grew dramatically
as a result of the HIV/AIDS pandemic. Clinical observations of immune deficiencies
leading to reactivation of toxoplasmosis was supported by studies in mice that showed
that depletion of CD4+ or CD8+ T cells during chronic infection resulted in TE 15, 18, 122124

. In addition to producing IFN-γ during toxoplasmosis, parasite-specific T cells also

have the capacity to lyse infected cells in immunization and rechallenge models 125, 126,
127, 128

. During toxoplasmosis, CD8+ CTL activity is partially dependent on the cytotoxic

molecule perforin, particularly during chronic infection 129, 130, though there is evidence
for perforin-independent pathways of lysing target cells 131, 132. There are also reports
that human CD4+ T cells can lyse T. gondii-infected cells 133, 134, but it is unclear whether
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this occurs in the mouse. Interestingly, though CTLs can lyse actively infected cells,
these events do not appear to result in the death of the intracellular parasite 135. Together,
these clinical observations and laboratory studies highlight the vital role for CD4+ and
CD8+ T cells that produce IFN-γ in the long-term control of T. gondii 18.
Summarized in Figure 2, control of T. gondii infection requires the coordinated
efforts of innate and adaptive responses. Innate recognition in professional APCs occurs
through stimulation of their pattern recognition receptors (PRRs). This activation leads
to production of pro-inflammatory cytokines such as TNF-α and IL-12 with the latter
stimulating NK cells to produce IFN-γ. IL-12 also enhances IFN-γ production from
parasite-specific T cells to create a pool of activated antigen-specific effector T cells that
control infection. IFN-γ activates anti-microbial responses that help restrain intracellular
growth of T. gondii. Together, the combination of innate cell production of IL-12 and T
cell cytolytic activity and secretion of IFN-γ induces a strong Th1 immunity that
effectively controls T. gondii replication and growth.
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Figure 2. The innate and adaptive immune response to T. gondii. A. Innate cell
populations such as neutrophils (Nφ), macrophages (Mφ), and dendritic cells (DCs)
recognize T. gondii through TLRs and PRRs as they phagocytose parasites or become
infected by them. Activated cells then produce inflammatory cytokines such as TNF-α,
that promotes intracellular killing, and IL-12. B. Secreted IL-12 is taken up by NK cells
inducing IFN-γ production; IL-12 also synergizes with antigen-presentation to T cells to
induce cytotoxic T cell responses and IFN-γ secretion. C. Activated NK cells and T cells
produce IFN-γ which acts on infected cells to upregulate effector mechanisms. D. Many
cell types respond to IFN-γ to activate anti-microbial responses including all
macrophages, neutrophils, and dendritic cells.
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IFN-γ-dependent effector mechanisms and parasite killing
As described in the previous section, NK and T cell production of IFN-γ is critical
to control T. gondii. The section will describe our current understanding of how IFN-γ
mediates protection through upregulation of effector molecules and how this pathway
synergizes with IFN-γ-independent mechanisms of killing such as CD40 ligation and
autophagy. It will highlight the cell types that are prominent “professional killers” of T.
gondii such as the macrophage and neutrophil and how these phagocytic cell types
mediate parasite clearance.
Macrophages represent one of the major arms of the immune system and have an
ability to kill intracellular microorganisms that is enhanced by IFN-γ 136. Many early
reports described the ability of macrophages to kill intracellular microbes such as T.
gondii, Mycobacteria, and Leishmania 137-141. These studies identified that macrophages
respond to IFN-γ to upregulate inducible nitric oxide synthase (iNOS) to produce of
oxygen-free radicals mice, although humans lack this enzyme 142, 143. iNOS converts Larginine into nitric oxide (NO), which is an oxidative burst thought to damage DNA and
limits rapid parasite replication . In vitro studies in mice have demonstrated that NO can
effectively kill parasites, or more precisely stall replication, leading to eventual clearance
through other mechanism described in Figure 3. However, although in vitro studies
presented NO as a powerful mediator of parasite killing, it was unexpected that iNOS-/mice were more resistant to T. gondii than IFN-γ-/- or IFN-γR-/- mice 144-147. Since NO is
required for chronic control but not acute control it suggests that mice have an additional
IFN-γ-dependent, iNOS-independent mechanisms to control parasite growth 148. An
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insight into these mechanisms was provided by Taylor and colleagues who identified a
critical role for a group of IFN-γ-dependent p47 Immunity-Related GTPases (IRGs) in
resistance to T. gondii in mice 149. IFN-γ-inducible p47 IRGs were identified as critical to
resistance to T. gondii as infected Irgm1-deficient mice succumbed acutely to infection
with kinetics similar to IFN-γ knockout mice 150. Similar reports using other similar
IRGs such as Irgm1 and Irgm3 identified a group of proteins with unknown function that
are required for resistance to a large number of pathogens including T. gondii,
Trypanosoma cruzi, Leishmania major, Chlamydia trachomatis, Mycobacterium
tuberculosis, Listeria monocytogenes, Salmonella typhimurium, and Legionella
pneumophila 12, 14, 151-160. Twenty-three p47 IRGs have been identified in mice, some of
which have a role in the control of distinct pathogens, but whose function is still poorly
understood 160, 161. Moreover, humans have only three described IRGs, one of which,
Irgm1, has been directly linked with autophagic clearance of Mycobacteria 156, 161. The
observation that humans have far fewer IRGs suggests that each may perform additional
tasks, have a broader spectrum of activity, or that there are additional human orthologs
161

.
How IRGs promote the control of T. gondii is not well understood. Studies have

shown that some IRGs such as Irgm1 and Irgm3, colocalize to the parasitophorous
vacuole and these events are associated with membrane stripping and characteristic
autophagic membranes proximal to the damaged PV that could be blocked with inhibitors
of autophagy 156, 161-166. Subsequent work by Subauste and colleagues demonstrated that
an autophagy gene, beclin1, was required for CD40-mediated killing of T. gondii by
macrophages in vitro 167, 168. Another classical autophagy protein, atg5, was shown to be
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linked to IRG functions as mice with a conditional deletion of atg5 in macrophages were
acutely susceptible to T. gondii and Listeria monocytogenes 169. Moreover, macrophages
lacking atg5 protein were unable to load IRGs effectively and destroy the PV suggesting
an intimate link between pathogen killing and autophagy.
While the studies described above focus on the role of autophagy in killing
mechanisms, there is also literature that suggests these events can influence the immune
system. As highlighted in Figure 3, there is evidence that autophagy is involved in major
histocompatibility complex (MHC)-restricted presentation of antigens and macrophages
deficient in another IRG, Irgm3, are defective in their ability to present T. gondii antigen
21

. Autophagic processing is also implicated in allowing intracellular Toll-like receptors

(TLR) access to ingested material, and this may serve as a positive feedback
mechanism in vivo to enhance antimicrobial effectiveness, although how this happens
during any infection is unclear 170. However, the current studies have not clearly
delineated whether most autophagy proteins direct killing themselves, or if atg5 is unique
in that has multiple functions 19, 168.
In addition to studies with T. gondii, autophagy is implicated in resistance to other
intracellular organisms including Listeria, Shigella, Mycobacterium, and herpes simplex
virus-1 (HSV-1) 171-176. That autophagy is needed in both Drosophila and mice for
defense against Listeria monocytogenes suggests that this process is fundamentally
important for multiple host species 176. This is further emphasized by the recognition that
many microorganisms have evolved mechanisms to evade, control, or usurp basic
autophagy pathways for their own survival. For example, some γ-herpes viruses encode
proteins in their genomes that antagonize autophagy proteins 177, 178. This suggests that
19

tampering with this process may be an important determinant of pathogenicity relevant to
numerous pathogen and that there is an important link between autophagy and IFN-γ
responses in parasite killing, but how these pathways intersect in vivo remains an open
question.
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Figure 3. The concerted actions of IFN-γ and autophagy in killing and disposal of
intracellular pathogens. IFN-γ binding to its cognate receptor (IFN-γR) induces
upregulation of both nitric oxide that limits pathogen replication inducing a state of
delayed replication or “stasis” and p47 IRGs (1) that are required for resistance to T.
gondii. Autophagy activators, such as nutrient depletion, TLR stimulus, or T celldependent CD40-CD40L ligation, activate atg5 (2) and the autophagic machinery that
colocalize with the IRGs at the parasitophorous vacuole (3). Once at the pathogen-host
interface, this complex induces vacuole degradation, lysosmal fusion, and autophagic
clearance of the parasite (4). This process induces proteasomal degradation (5) and may
allow subsequent loading of pathogen peptides onto MHC molecules for presentation to
T cells (6).
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IL-6 and T. gondii
IL-6 is a pleiotropic cytokine with multiple functions during toxoplasmosis.
Historically considered an inflammatory cytokine, infection of IL-6 knockout mice with
T. gondii resulted in increased susceptibility to TE 179. However, the pleiotropic nature of
IL-6 was confirmed when chronically infected mice were treated with neutralizing
antibodies to IL-6 and demonstrated reduced disease with fewer parasite cysts suggesting
that IL-6 promoted parasite growth 180. Recently, there has been renewed interest in the
biology of IL-6 due to many new discoveries including the finding that IL-6 regulates the
balance between Th17 cells and regulatory T cells (Tregs) 181-184. Th17 is required for
defense against several intracellular pathogens such as T. gondii, Yersinia pestis,
Staphylococcus aureus, and Klebsiella 185-189. Additionally, IL-6 has been shown to be
important for NK cell function, neutrophil recruitment, B cell differentiation, and DC
maturation (Silver unpublished studies) 190-195. Furthermore, IL-6 biology is complex and
these studies described and those presented herein highlight some of the diverse functions
that IL-6 plays during infection.

Biology of IL-6
In 1968, T and B lymphocytes were discovered to play important roles in the
production of antibody 196. B cells were shown to produce antibodies but only when T
cells were present and suggested that there was a secreted factor that stimulated growth
and differentiation of B cells. Subsequent studies on a cell line created from a patient
with B cell leukemia identified this growth factor as IL-6, and it was confirmed to be the
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same molecule as B-cell stimulatory factor-2 (BCSF-2), IFN-β2,
Hybridoma/plasmacytoma growth factor, and hepatocyte stimulating factor (HSF) 197, 198.
Subsequent studies using anti-IL-6 antibodies as well as IL-6 knockout mice were critical
in identifying IL-6 as being involved in multiple pathways of inflammation, oncogenesis,
and resistance to multiple infections 199-201.
While IL-6 and its biological effects have long been studied, it was the recent
identification of IL-17-producing CD4+ T cells (Th17) and their role in inflammation that
renewed interest in the cytokine 185-189. IL-6 is an important mediator of the balance
between Th17 cells and Tregs and drives IL-17 production from CD4+ T cells 181-184.
Transforming growth factor β (TGF-β), was shown to induce regulatory T cells (Tregs)
alone, but when combined with IL-6, TGF-β could induce Th17 cells 202-206. These two
T-cell subsets have important immune functions: Th17 cell is involved in the
pathogenesis of autoimmune diseases and protection against certain infections such as the
Klebsiella and T. gondii, while Tregs control excessive effector T-cell responses and
highlight the important functions of IL-6 and Th17 in immunity and immune-pathology
207, 208

.

Clinical diseases associated with IL-6
Overproduction of IL-6 has been associated with multiple clinical diseases
including rheumatoid arthritis (RA), Castleman's disease, juvenile idiopathic arthritis
(JIA), and multiple myeloma 209-215. Experimental animal models of RA using IL-6gene-deficient mice showed no increase in joint inflammation suggesting that IL-6 was
important for inducing this disease. Additionally, cultures of patient synovial cells
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combined with their peripheral mononuclear cells demonstrated that osteoclast generation
was inhibited by the addition of the anti-IL-6R antibody 216. As a result, antibodies to the
receptor to IL-6 (αIL-6R) were administered as a treatment for rheumatoid arthritis (RA),
Castleman's disease, juvenile idiopathic arthritis (JIA), and multiple myeloma 209-215. αIL-6R had been used experimentally since the 1990s but was approved for clinical use in
the USA in 2010 under the name tocilizumab 217, 218. Overall, the positive clinical results
from using tocilizumab have identified a beneficial effect of limiting IL-6-mediated
inflammation for certain diseases.

gp130 Signaling
Given the important role for IL-6 in immune function, considerable effort has been
undertaken to understand how the signaling of IL-6 works. IL-6 and its family of
cytokines which include IL-11, ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT1), cardiotrophin-like cytokine (CLC), leukemia inhibitory factor (LIF), neuropoietin
(NPN), oncostatin M (OSM), IL-27, and IL-31 all utilize a receptor complex consisting
of at least one gp130 signaling molecule (reviewed in 219). Gp130 was discovered in
1978, and it is now appreciated that gp130 is associated with the signaling of a number of
cytokines. Thus, when IL-6 binds to the IL-6R, it triggers a heterodimeric association
with gp130 to form a signaling complex composed of a gp130 homodimer plus two IL6Rα chains. The cytoplasmic domain of IL-6Rα is not necessary for signal transduction
and the binding of IL-6 to its receptor triggers the association of IL-6Rα with gp130,
leading to the formation of a hexamer composed of two each of IL-6, IL-6Rα and gpl30.
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Gp130 is expressed by most cells in the body while IL-6Rα is mainly expressed by
hepatocytes, neutrophils, monocytes/macrophages, and some lymphocytes. Additionally,
a soluble form of the IL-6Rα (sIL-6Rα) is generated by either limited proteolysis of the
membrane protein or translation from an alternatively spliced mRNA 220. A unique
property of IL-6, “trans-signaling,” as it has been termed, is possible as cells that express
gp130 can respond to stimulation with IL-6 when co-cultured with sIL-6Rα 221-223. One
functional consequence of this is that infiltrating neutrophils can cleave the membrane
IL-6Rα, thus generating the sIL-6Rα, allowing IL-6 to signal to local cells expressing
only the gp130 subunit 221. Mice engineered to express soluble gp130 blocks IL-6 transsignaling and have defective inflammatory responses characterized by decreased
infiltration of neutrophils and monocytes to the site of inflammation.
Stimulation of gp130 triggers the activation of three signaling cascades, most
prominently the JAK-STAT pathway. A family of kinases located near gp130 on the cell
surface called Janus kinases and include JAK1, JAK2, JAK3 and tyrosine kinase 2 are
phosphorylated following receptor binding and activation. These enzymes then
phosphorylate various STAT molecules, which allows these molecules to translocate to
the nucleus and initiate gene transcription. Signaling through gp130 can activate STAT1,
STAT3, and STAT5. Engagement of gp130 also leads to the recruitment of the
cytoplasmic protein tyrosine phosphatase SHP2, which activates the Ras-ERK1/2 MAPK
and PI3K/AKT pathways.
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JAK/STAT signaling and the biology of SOCS proteins
Growth, differentiation, and other functions of immune and hematopoietic cells are
controlled by multiple cytokines, which signal through cognate receptors. The Type I
cytokines, which include those that use through gp130, signal in part through the
JAK/STAT pathway and many of these signaling cascades are regulated by SOCS
proteins. Although these receptors often do not catalyze reactions themselves, they serve
as docking sites for a family of kinases called Janus kinases (JAKs) 224. Upon ligation,
cytokines induce homo- or hetero-dimerization and activation of their receptors and
induce the phosphorylation and activation of the JAKs, of which there are 4 known (JAK
1-3, Tyk2) 225, 226. Once activated, the JAKs phosphorylate the receptor, creating docking
sites for SH2-containing signaling proteins, such as STATs, which in turn can be
phosphorylated by the JAKs 226. As with many signaling cascades, there are feedback
mechanisms that regulate cytokine-mediated JAK-STAT signaling that include
dissociation of JAK/STAT proteins from the receptor complex, endocytosis and
degradation of the receptor, and nuclear export of phosphorylated STAT molecules.
However, Suppressors of Cytokine Signaling (SOCS) proteins are the primary negative
regulators of JAK/STAT signaling 227, 228. These proteins have similar homology to each
other and tend to be specific for particular cytokine signaling cascades. Many of these
proteins are upregulated in settings of inflammation and infection.
Although initially described for Interferon signaling, JAK/STAT signaling has been
observed for a number of cytokines, growth factors, and hormonal factors. Cytokines
often induce the phosphorylation of multiple STAT molecules as well as other signaling
proteins such as MAP kinsases, phosphatidyl-inositol-3 (PI3) kinase, and phospholipase
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C-c (PLCc) 229-232. Interactions between these signaling pathways are likely to
differentiate between an IFN-γ-induced phosphorylation of STAT1 from an IL-6-induced
phosphorylated STAT1 although this area is poorly understood.
Gene knockouts for many of these molecules have elucidated their biological
functions. For example, JAK1-deficient mice cannot respond to a wide range of cytokines
including those whose receptors utilize the common γ-chain and those that use gp130 233,
234

. JAK2 gene disruption causes embryonic lethality due to impaired erythropoiesis

while JAK3 deletions causes severe immunodeficiency 235, 236. Mice that lack specific
STAT proteins are viable but demonstrate abnormalities related to impairments in certain
cytokines; for instance, STAT1 knockouts have impairments in IFN-mediated signaling
237

, STAT4 knockouts have a defect in IL-12 signaling 238, 239, and STAT6 knockouts

cannot signal through IL-4 239. Thus, the combination of biochemical and genetic studies
of STAT proteins has led to a more thorough understanding of how these molecules
function.

SOCS proteins
SOCS proteins were first identified through a genetic screen for inhibitors of IL-6
signaling 240. Currently, there are 8 known SOCS proteins in mice, numbered SOCS1-7
plus the cytokine-inducible SH2 protein (CIS), these proteins have been shown to have
important roles as negative regulators of multiple cytokines 241, 242. These molecules are
characterized by a central SH2 domain and a C-terminal 40-amino-acid module called the
SOCS box. Although they are similar in protein structure, they can have profoundly
different functions in vivo.
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The proposed mechanisms of function for many of the SOCS proteins are described
in Table 1. CIS and SOCS2 can sterically hinder the STAT binding sites of receptors
presumably using their SH2 domain as a pseudo-receptor 243-246. Nevertheless, based on
studies using SOCS2-deficient mice 247, SOCS2 seems to be a relatively specific negative
regulator of the GH−STAT5 pathway. SOCS5 has been proposed to inhibit IL-4
signaling by interacting with the IL-4Rand inhibiting binding of JAK1 248. Both SOCS1
and SOCS3 can inhibit JAK tyrosine kinase activity through a kinase inhibitory domain
(KIR) located within the N-terminal domain, which either prevents binding directly or
acts as a pseudosubstrate 249-251. SOCS1 uses its SH2 domain to directly bind the
activation loop of JAKs and binds the catalytic pocket of JAKs through its KIR 251. As
SHP-2 can promote gp130 signaling through the activation of MAP kinases, SOCS3 may
also suppress gp130 signaling by competing with SHP-2 for the receptor although it is
possible that SHP-2, a phosphatase, may negatively regulate gp130 signaling by
dephosphorylating the associated JAKs 252-254. Additionally, SOCS proteins have a
SOCS box which has been shown for some of the SOCS family members to interact with
ubiquitination molecules elongins B and C, cullins, Rbx-1 and E2 to function as an E3
ubiquitin ligases and mediate the degradation of proteins associated through their Nterminal regions 255-258. Therefore, SOCS proteins seem to combine targeted inhibition of
JAKs and STATs with a general mechanism of proteasomal degradation for intended
substrates. Interestingly, the SOCS box is also important for the stabilization and/or
degradation of the SOCS1 and SOCS3 proteins themselves as interaction of the SOCS
box with elongin C stabilizes SOCS3 protein expression whereas phosphorylation of the
SOCS box enhances proteasome-mediated degradation of SOCS3 255-258. The role that the
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SOCS box plays in other SOCS proteins remains unclear.

SOCS3 regulates signaling through gp130
Many cytokines activate STAT3, including IL-6 and IL-10, yet they yield unique
patterns of transcription and biological functions but it was unclear how STAT3 signals
could be differentially regulated. Historically, IL-6 has been considered a proinflammatory cytokine as it played a prominent role in many inflammatory and
autoimmune diseases, while IL-10 is an immunoregulatory cytokine that has potent antiinflammatory activity, including the suppression of TLR activation and NF-κB-mediated
genes 259-266. While it was known that STAT3 is essential for the biological actions of
both IL-6 and IL-10, it was unclear how the two STAT3 signals could be differentiated to
provide such polar opposite functions. In 2003, SOCS3 was shown to provide at least
one possible mechanism for how this was possible 267. Both IL-6 and IL-10 activate
STAT3 however only IL-6 does so through use of the gp130 subunit. In a study by
Yasukawa et. al., it was shown that the inhibitory effects of SOCS3 are due to its ability
to specifically bind to the phosphorylated tyrosine residue 759 on gp130 and that this
binding led to an inability of STAT3 to dock and/or be phosphorylated following receptor
stimulation 267. As SOCS3 is upregulated by both IL-6 and IL-10, the researchers
observed that the preferential binding of SOCS3 to the IL-6R limited its response and this
provided the mechanism for observed differences in signaling between the cytokines as
IL-6 and IL-10 function. More precisely, in the absence of SOCS3, IL-6 had has
phenotypically similar inhibitory properties as IL-10. Additionally, injection of SOCS3
conditionally-deleted mice with a lethal dose of LPS led to survival of the mice
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associated with impaired TNF-α and IL-12 responses 267. This suggested that SOCS3
specifically acted on IL-6 signals during inflammation and was a strong inhibitor of its
inflammatory properties although very little was understood about what this meant in
vivo.
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Protein
SOCS1
SOCS2

Phenotype of knockout mice
Severe inflammation, neonatal death
Gigantism

SOCS3

Defects in erythopoiesis, embryonic lethal

SOCS4
SOCS5
SOCS6
SOCS7
CIS

None/unknown
Unknown, possible T cell defects
Mild growth retardation
None/unknown
Hematopoietic deficiencies

Cytokines
IFN-γ
GH, IGF,
PRL, IL-2,
IL-3, EPO,
LIF, EGF,
leptin and
IFN-α
gp130, LIF,
leptin
EGF
STAT6
IGF
IGF
EPO, IL-3

Mechanism of regulation
1,3,4
1,2

1,2?
2
Unknown
2
Unknown
1,4

Table 1. List of phenotypes associated with SOCS gene deletions. Listed are the
eight known SOCS proteins, their phenotype in knockout mice, the cytokines believed to
be involved or regulated by the particular SOCS protein and the proposed mechanism of
action by which it exerts its regulatory effect. 1. Inhibition of STAT protein binding
either by steric hindrance of STAT binding. 2. Ubiquitination of JAK, STAT, or another
directly involved protein. 3. Inhibition of the JAK kinase activity through use of its KIR
or kinase inhibitory region. 4. Acts as a psuedoreceptor for docking of STAT proteins.
GH: Growth Hormone; IGF: Insulin Growth Factor; PRL: Prolactin; EPO:
Erythropoietin; LIF: Leukemia Inhibitory Factor; EGF: Epidermal Growth Factor
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II.

The Role of Macrophage STAT3 Signaling in
Resistance to T. gondii
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Abstract
Resistance to the intracellular parasite Toxoplasma gondii is dependent upon
interferon-γ (IFN-γ) signaling which upregulates an array of genes involved in antimicrobial immunity. These genes encode both pro-inflammatory cytokines and effector
molecules that allow infected cells to kill this pathogen. T.gondii has developed multiple
mechanisms to evade this response including the ability to activate STAT3 in host cells
that inhibits inflammatory processes. Recent studies have described this phenomenon;
identifying a secreted parasite kinase, ROP16, as the protein responsible for direct
phosphorylation of STAT3 resulting in inhibition of pro-inflammatory cytokines,
particularly IL-12. Other studies have suggested that this STAT3 activation was straindependent and might provide a mechanism for virulence differences in vivo.
Additionally, it was hypothesized that removal of STAT3 from macrophages would
eliminate a pathway that promotes parasite replication leading to enhanced resistance in
vivo. Data provided here indicate that macrophages lacking STAT3 produce similar
levels of pro-inflammatory cytokines and mice with a deletion of STAT3 in macrophages
(LysM-cre Stat3fl/fl) have comparable resistance to wild type mice when infected.. These
data suggest that parasite-induced STAT3 signaling in macrophages may not be as
critical to resistance to T. gondii as previously considered.
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Introduction
T. gondii has many mechanisms to interfere with host-cell signaling that includes
its ability to interfere with STAT1 and NF-κB signaling as well as to induce the
phosphorylation of STAT3 268-270. Several studies have described this latter phenomenon,
suggesting that T. gondii releases the rhoptry kinase ROP16 upon infection to directly
phosphorylate STAT3 86, 87, 270, 271. Since STAT3 is the predominant transcription factor
for the anti-inflammatory cytokine IL-10, it was hypothesized that these events induced
an IL-10-like transcriptional profile that would restrict inflammatory responses from
macrophages. As a result of these combined efforts, infection of a macrophage by T.
gondii would impair STAT1 and NF-κB signaling making the cell less responsive to
IFN-γ and TLR stimuli and also induce the anti-inflammatory responses driven by
activation of STAT3.
Previous studies showed that T. gondii induces the rapid phosphorylation of
STAT3 that correlates with a reduction in the ability of these macrophages to produce
TNF-α and IL-12p40 87, 270. It was also reported that the avirulent strain Prugniaud (Pru),
but not the more virulent RH strain, induced the production of IL-12p40 from resting
macrophages 87. Work from other groups suggested that the Pru does not activate STAT3
as efficiently as RH does and this underlines the disparity in IL-12 production which
might account for the observed differences in virulence 87, 272. Data presented here
demonstrate that despite basal differences in IL-12 production from infected
macrophages, Pru phosphorylated STAT3 in macrophages similarly to RH and both
strains were able to inhibit pro-inflammatory cytokines from macrophages equally.
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Although no in vitro differences in STAT3 signaling between parasite strains
could be observed, studies showed that a secreted rhoptry protein (ROP16) was a key
virulence factor that could directly phosphorylate STAT3 upon injection in a cell 86, 87, 272.
Additionally, when transgenic mutants were made by overexpressing ROP16 from a less
virulent strain in RH, virulence could be attenuated and this was associated with
increased IL-12 production 87. These results supported the hypothesis that STAT3
signals in vivo were important for T. gondii virulence by limiting the protective IL-12
response. However, when mice containing a conditional deletion of STAT3 in
macrophages and neutrophils (LysM-cre Stat3fl/fl mice) were infected, no detectable
difference in IL-12 production or IFN-γ production was found. However, during the
chronic phase of infection, parasite DNA in the brain was lower in LysM-cre Stat3fl/fl
mice than control Stat3fl/fl mice although survival was similar. These data suggest that
STAT3 in macrophages is not required for resistance to T. gondii in vivo. Surprisingly,
despite observed in vitro differences, the loss of STAT3 in macrophages did not lead to
increased IL-12 concentrations in vivo indicating that T. gondii may target IL-12 from
other cell types or that the increased macrophage-activation predicted by removal of
STAT3 does not affect overall IL-12 production.
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Materials and Methods
Mice and infections
LysM-cre Stat3fl/fl mice were originally generated by Peter Murray as previously
described 270. C57/Bl6 mice were obtained from Taconic Farms Inc (Germantown, NY).
C57/Bl6, Socs3fl/fl, and LysM-cre Stat3fl/fl mice were bred in the University Laboratory
Animal Resources facilities at the University of Pennsylvania. All procedures were
performed in accordance to the guidelines of the University of Pennsylvania Institutional
Animal Care and Use Committee. RH and Prugniaud (Pru) parasites were grown in
Human Foreskin Fibroblast (HFF) monolayers cultured with D10 media (DMEM, 25%
M199 Supplement, 10% Fetal Bovine Serum, 0.5% penicillin/streptomycin (10,000
µg/mL), 0.5% gentamycin (50 µg/mL)) and harvested as previously described 273. Bonemarrow derived macrophages (BMMφ) were flushed from mouse femurs and grown for 6
days in DMEM containing 1% sodium pyruvate, 1% penicillin/streptomycin, 10% FBS,
30% L929 cell supernatant, and 1% HEPES 269, 273. All infections were performed i.p.
with 104 parasites.

Immunoblotting
106 BMMφ were cultured in 96 well plates overnight and then infected with 5:1 Pru
parasites for the indicated durations. Lysates were prepared using TNT buffer (0.1 M
Tris-HCl, pH 7.5, 0.15 M NaCl, and 0.05% Tween 20) combined with complete protease
inhibitors (Roche, Mannheim, Germany) at 1:100 for 20 minutes on ice and then stored at
-20°C. Samples were electrophoresed and transferred to Immobulon-P membrane
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(Millipore, Bedford, MA) and blocked for 1 hr in 5% nonfat dry milk and probed
overnight with mouse monoclonal antibodies to SOCS3 (Invitrogen, Carlsbad, CA), βactin, pSTAT3, and total STAT3 (Cell Signaling, Danvers, MA). Blots were washed in
TBS-Tween 3 times and probed with α-mouse or α-rabbit secondaries conjugated to
horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA) at 1:10,000 for 1 hr
at room temperature. Blots were washed 3 times and developed with enhanced
chemiluminescence and exposed to film. Results are representative of two independent
experiments.

Cytokine and flow cytometric analysis
Whole splenocytes were washed and resuspended in complete RPMI 1640 (Invitrogen)
containing 10% FBS (Serum Source International), 1% penicillin/streptomycin
(Invitrogen), 1 mM sodium pyruvate (Mediatech, Manassas, VA), 2 mM L-glutamine
(Mediatech), 0.1% 2-mercaptoethanol (Invitrogen) before being plated at a cell density of
106 cells per well in a final volume of 200 µl in 96-well plates (Costar, New York). Cells
were stimulated with or without soluble Toxoplasma antigen (STAg) at 50 µg/mL, or αCD3 at 1µg/mL (eBioscience) for 24 hr at 37 C in 5% CO2. Brain mononuclear cells
(BMNCs) were isolated as previously described 274, 275. Perfused brains were cut into
small pieces, passed through an 18 gauge needle, and digested with collagenase/dispase
and DNase (Roche) for 90 min. Following the digestion, the cells were washed and
strained through a 70 µm filter. Subsequently, cells were resuspended in 60% percoll,
overlayed with 30% percoll, and centrifuged at room temperature for 25 min at 2000 rpm.
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BMNCs were collected from the interface, washed, and enumerated. For T cell recall
responses, splenocytes were plated at 500,000 cells/well and BMNCs at 200,000
cells/well. Peritoneal cells were isolated as previously described 25 and cell-free
peritoneal wash fluid was used for cytokine analysis. Concentrations were normalized to
the amount of peritoneal fluid recovered from each mouse. Blood was collected via
cardiac puncture. Concentrations of IFN-γ, IL-12p40, and IL-6 were determined by
ELISA using antibodies from eBioscience (San Diego, CA). Freshly isolated PECs from
infected mice were incubated with Fc block (0.1 µg/mL 24G2 antibody) for 15 min prior
to surface staining with Ly6C-PerCP 5.5 (HK1.4), CD11b-FITC (M1/70), F4/80-eFluor
780 (BM8), GR1-PECy7 (RB6-8C5), CD86-APC (16-10A1), CD80-PE (GL1), NK1.1PE (PK136), CD4-eFluor 780 (RM4-5), CD8-PerCP 5.5 (53-6.7), CD19-PECy7
(eBio1D3 (1D3)), CD11c-APC (N418), CD62L-APC (MEL-14), and CD44-PE (IM7)
(eBioscience, San Diego, CA), MHC Class II I-A/I-E (Biolegend, M5/114.15.2), CD3εPacific Blue (500A2), and CD19-Pacific Blue (1D3) (BD Biosciences). 106 PECs were
plated in RPMI 1640 and stimulated with PMA (50 ng/mL) and ionomycin (500 ng/mL)
in the presence of brefeldin A (10 µg/mL) (Sigma) for 4 hrs at 37 °C with 5% CO2 unless
otherwise noted. The cells were fixed with 2% paraformaldehyde following surface stain.
(Electron Microscopy Science, Hatfield, PA) for 10 min. For intracellular staining, the
cells were permeabilized with 0.5% saponin (Sigma, St. Louis, MO) and stained with
anti-IFN-γ-APC (XMG1.2) or IL-12p40-APC (17.8) (eBioscience). All flow cytometry
was performed on a FACSCanto using FACSDIVA 6.0 software (BD Biosciences, San
Jose, CA). Analysis was performed using FlowJo software (Treestar Inc., Ashland, OR).
Experiments were performed twice with similar results.
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In vitro killing assay and inhibition assays
5x105 BMMφ were harvested and cultured in 96 well plates and pretreated overnight with
media alone or IFN-γ (BD Biosciences, San Jose, CA) and TNF-α (eBioscience) at
indicated concentrations. Cells were infected with Pru at 1:1 and incubated overnight.
Cells were then centrifuged onto microscope slides and the number of infected
macrophages was counted. Nitrite analysis was performed using the Griess protocol 276.
Briefly, 50µl of sample was added to equal volume of a mixture (1:1) of 1%
sulfanilamide and 0.1% naphthylethylenediamine in 2% (vol/vol) phosphoric acid. After
incubation at room temperature, the optical density of the reaction product was measured
at a wavelength of 540 nm and the nitrite concentration was calculated with sodium
nitrite as a standard. For parasite cytokine-inhibition assays, 2x105 BMMφ were plated
and infected with either RH or Pru parasites at an MOI of 1:1 for 1 hr prior to LPS
stimulation (100 ng/mL, Sigma) for 24 hours. For IL-6 inhibition assays, BMMφ were
stimulated with IFN-γ (10ng/mL) and LPS (10ng/mL) with or without IL-6 (10 ng/mL) at
10 fold increments beginning at 0.001 ng/mL (eBioscience) or α-IL-6 (100 ng/mL,
BioXcell). ELISAs of supernatants from 24 hr cultures were performed using antibodies
for IL-12p40 and TNF-α (eBioscience).

Statistical analysis
Statistical analysis was conducted Students’ t test or One-Way ANOVA and correlations
were calculated with Prism software (Graphpad Software).

39

Results
T. gondii induces strain-independent phosphorylation of STAT3 in
macrophages
Many genotypic differences have been suggested to account for variances in
virulence observed between the three clonotypic strains of T. gondii. Recently, it has
been described that virulent Type I strains induce the phosphorylation of STAT3 more
prominently than Type II strains and subsequently could inhibit IL-12 production more
effectively 87, 271. This idea was supported by data that showed that the ROP16 molecule
of a type I strain, RH, elicited a more robust phosphorylation of STAT3 associated with
lower IL-12 responses when transferred to a type II, Pru. However, these studies
measured pSTAT3 in a fibroblast cell line rather than primary macrophages where the
IL-12 was measured 87. In order to address whether type I strains truly had better
inhibitory qualities than type II strains in vitro, the kinetics of STAT3 signaling and
subsequent IL-12 production was assayed using ΒΜΜφ.
To determine if there were strain-specific differences in the ability of T. gondii to
phosphorylate STAT3 in macrophages, ΒΜΜφ were infected with RH and Pru at an
M.O.I. of 5:1. Phosphorylated STAT3 was identified by western blot at 30 minutes postinfection for both RH and Pru and remained detectable for up to 4 hours (Figure 4A).
These data suggested that Pru phosphorylates STAT3 similarly to RH yet only Pru can
elicit IL-12 from otherwise unstimulated macrophages. When ΒΜΜφ were infected for
24 hours with either strain, Pru elicited significantly greater IL-12p40 production than
RH (p<0.001) (Figure 4B). This was the only pro-inflammatory molecule that was
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detected in the supernatants of BMMφ infected with RH or Pru as TNF-α, IL-6, nitric
oxide (NO), IL-10, CCL3, CCL4, or CCL5 production could not be observed (data not
shown). These data suggest that either Pru promotes the production of IL-12p40 or that
RH has an additional mechanism to suppress IL-12p40 that the avirulent Pru lacks.
Phosphorylation of STAT3 by T. gondii is associated with the inhibition of proinflammatory responses by activated macrophages. To determine if Pru can inhibit
macrophage responsiveness similarly to RH, ΒΜΜφ were infected for 1 hr with either
strain or given soluble toxoplasma antigen (STAg) as a followed by 24hrs of LPS
stimulation. Infection with either strain dramatically reduced the ability of macrophages
to produce IL-12p40, TNF-α, IL-6, or NO (Figure 4C). STAg stimulation had significant
effects on TNF-α but these were not as prominent as with live parasites while STAg
stimulation also significantly enhanced nitrite production following stimulation (Figure
4C). STAg also induced no significant change in IL-12p40 or IL-6 that suggest that live
parasites are more efficient inhibiters of cytokine production. IL-10, however, was not
shown to be upregulated following LPS stimulation alone, but enhanced following RH
and STAg stimulation (p<0.05) (Figure 4D). Curiously, Pru seemed to have no effect on
IL-10 production. This supports data published suggesting that infection with RH does
not interfere with overall protein translation or secretion but rather specifically targets
certain genes for downregulation (i.e. IL-12p40) while upregulating other antiinflammatory genes (i.e. IL-10) 277. No difference in chemokine production was found
between the two strains for CCL3, CCL4, and CCL5 following LPS stimulation (Figure
4E). These data suggest RH and Pru have similar mechanisms to downregulate certain
pro-inflammatory responses while RH has additional mechanisms that alter IL-12p40 and
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IL-10 responses. Previous studies indicated that RH inhibited TNF-α and IL-12p40 in a
STAT3-dependent manner 270, therefore it implies that the ability of RH to inhibit NO
and IL-6 is also STAT3-dependent although these experiments were not performed.
However, it is interesting that Pru, which here has very similar effects on these cytokines
as RH, was shown to phosphorylate STAT3 just as effectively as RH, which contradicts
previous studies 87. Therefore, further investigation is required to determine if the effects
of the parasites on IL-6, NO, and IL-10 are also STAT3-dependent.
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Figure 4.

Pru but not RH induces IL-12p40 from unstimulated macrophages while

both strains phosphorylate STAT3 and limit pro-inflammatory cytokine release
from activated macrophages. RH was shown to more strongly phosphorylate STAT3
in fibroblasts than Pru and this was associated with diminished IL-12 responses. In order
to determine if type I and type II strains of T. gondii affect STAT3 signaling and cytokine
production differently, BMMφ were incubated with either strain of the parasite and cells
were measured for phosphorylation of STAT3 or cytokine production. A) Both RH and
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Pru induced the phosphorylation of STAT3 by 30 minutes post-infection of unstimulated
macrophages. The signal diminished for STAT3 by about 4 hours for both strains of
parasites and is nearly absent by 24 hrs. B) RH and Pru were incubated with bonemarrow macrophages and the supernatants were measured for IL-12p40 after 24 hrs. RH
induced a non-significant increase in IL-12p40 concentration that was much lower than
Pru (p<0.01). C) RH and Pru inhibited pro-inflammatory cytokine release from LPSstimulated macrophages. Cells were infected for 1 hr and then stimulated for 24 hrs with
LPS (100 ng/mL) and measured for cytokine production. STAg was used as a control for
live parasites. Both strains of parasite were able to impair TNF-α, IL-12p40, NO, and
IL-6 production from macrophages while STAg largely could not. D) RH enhanced IL10 production from stimulated macrophages suggesting that its inhibitory actions are
specific for pro-inflammatory molecules. E) Neither RH nor Pru affected the production
of the chemokines CCL3, CCL4, and CCL5 from LPS-stimulated macrophages
indicating that the inhibitory properties of T. gondii are specific for certain proinflammatory molecules but not others. Experiements were repeated twice with similar
results. Mean +/- SD. Western blots were performed by Carolyn M. Gray.
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STAT3 is not required for induction of IL-12 by Pru
Previous studies identified a role for STAT3 in inhibiting IL-12 production from
macrophages infected with T. gondii independently of IL-6 and IL-10 87, 270. These
studies suggested that RH more efficiently phosphorylated STAT3 than Pru in order to
reduce pro-inflammatory cytokine production and that these effects caused the observed
in vivo differences in virulence.87. Figure 4 demonstrated that Pru phosphorylates STAT3
as effectively as RH upon infection but that only Pru induced IL-12p40 from
unstimulated macrophages. To determine if this difference in IL-12p40 production was
STAT3-dependent, control and STAT3-deficient macrophages were infected with either
RH or Pru for 24 hours and the supernatant cultures were measured for IL-12p40. As
shown in Figure 5A, Pru but not RH induces the production of IL-12p40 from
macrophages for both control and STAT3-deficient macrophages. This suggests that
when STAT3 is absent, there is still a difference between RH and Pru in the production
of IL-12p40 from macrophages.
Binding of IL-10 to its receptor leads to the phosphorylation of STAT3 and this
activation is associated with the inhibitory functions of this cytokine. Therefore, in the
absence of STAT3 in macrophages, it is conceivable that these cells may display
enhanced pro-inflammatory properties such as increased IL-12 or TNF-α production as
endogenous IL-10 cannot signal. To directly assess this, control and STAT3-deficient
BMMφ were analyzed for their ability to produce these cytokines when stimulated with
IFN-γ and LPS. Curiously, there was no increase in production of either IL-12 and TNFα following stimulation of STAT3-deficient macrophages as compared to wild type
macrophages (Figure 5B). This suggested that STAT3 may not be required for inhibition
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of these responses although with controlling for other inhibitory cytokines in the culture
such as IL-10, it is difficult to conclude that these effects are STAT3-independent.
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Figure 5. Macrophages deficient in STAT3 produce comparable pro-inflammatory
cytokines as wild type macrophages. BMMφ do not require STAT3 for production of
IL-12p40 following Pru infection or the production of IL-12p40 and TNF-α from
stimulated macrophages. 2.5x105 BMMφ were infected with RH or Pru for 24 hours and
the supernatants were measured for IL-12p40 (n=3). A) Pru induced a higher
concentration of IL-12p40 from control macrophages than RH (p<0.05). Macrophages
deficient in STAT3 (LysM-cre Stat3fl/fl) produced similar concentrations of IL-12p40
following infection with either strain suggesting that STAT3 is not required for this
phenomenon. Mean +/- SD. B) BMMφ were stimulated with IFN-γ (100 Units/mL) and
LPS (100ng/mL) for 24 hours and supernatants were measured for TNF-α and IL-12p40
by ELISA. STAT3 macrophages produced similar levels of cytokine following
stimulation as control macrophages. Results are indicative of two independent
experiments.
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LysM-cre Stat3fl/fl mice are resistant to T. gondii
The in vitro studies described in the previous sections suggest a limited role for
STAT3 in macrophages in vivo. However, macrophages receive multiple inflammatory
stimuli following infection and it is conceivable that these pro-inflammatory signals have
in vivo consequences that are not observed in these culture conditions. Although these
data suggest otherwise, evidence from the literature suggest that infection of LysM-cre
Stat3fl/fl mice would lead to a phenotype that reflected the ability of these mice to induce
enhanced Th1 responses with more efficient control of parasites 86, 87, 270. However, when
Stat3fl/fl and LysM-cre Stat3fl/fl mice were infected i.p. with the lethal RH strain at a low
dose of 103 parasites i.p., all mice succumbed to infection by day 8 (Figure 6A).
Additionally, a less virulent RH strain that expresses the Pru ROP16 (RH-Rop16) was
used to infect these mice with a high dose (1000 cysts, data not shown) or a low dose
(500 cysts, Figure 6B) administered by oral gavage and there was no significant
difference in mortality. These data suggest LysM-cre Stat3fl/fl mice do not show enhanced
resistance to the more virulent strains or high doses of T. gondii.
Type II strains cause lethal inflammation in IL-10 knockout mice, therefore it was
hypothesized that infection of LysM-cre Stat3fl/fl mice with Pru or Me49 might have
similar consequences 26. Stat3fl/fl and LysM-cre Stat3fl/fl mice were infected i.p. with Pru
(Figure 6C) and both intraperitoneally (data not shown) and by oral gavage (Figure 6D)
with Me49. None of these infections produced differences in mortality and all mice
survived challenge out to 50 days.
LysM-cre Stat3fl/fl mice demonstrate similar resistance to T. gondii compared to
wild type mice in terms of survival, but the literature suggested that markers of
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inflammation might be enhanced in these mice 270. At 10 days post infection with Pru,
very few parasites could be identified in the peritoneum of Stat3fl/fl and LysM-cre Stat3fl/fl
mice (data not shown). The total number of peritoneal cells was appeared greater in
LysM-cre Stat3fl/fl than control Stat3fl/fl mice but this was just above the level for
consideration of statistical significance (p=0.06) while the total number of spleen cells
was similar between groups of mice (Figure 7A,B). This suggested that LysM-cre
Stat3fl/fl mice have greater inflammatory response during acute infection. STAT3
activation is associated with an impairment of pro-inflammatory responses from
macrophages, therefore, the production of pro-inflammatory cytokines was measured
from mice acutely infected with T. gondii. However, in LysM-cre Stat3fl/fl mice there was
comparable IL-12p40 or IFN-γ production in the serum of mice infected for 10 days
(Figure 7C). Curiously, IL-10 production was significantly decreased in the sera of
LysM-cre Stat3fl/fl compared to control mice and supports data that IL-10 positively
regulates its own production in a STAT3-dependent manner (Figure 7D) 278.
Surprisingly, although there was diminished IL-10, this did not lead to more prominent
changes in the inflammatory response. Given the prominent role that STAT3 plays in
macrophages in vitro, it was surprising that at some level, these mice did not show
enhanced inflammation as evidenced by increased mortality. However, further
investigation would be required to strengthen the conclusion that STAT3 in macrophages
does not reduce inflammation in vivo.
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Figure 6. LysM-cre Stat3fl/fl mice show no significant difference in mortality
compared to wild type mice for multiple infection models of T. gondii. To determine
if LysM-cre Stat3fl/fl mice are hyper-resistant to both virulent and avirulent strains of T.
gondii, oral and intraperitoneal infectious were performed with multiple strains of T.
gondii. A) 5 mice per group were infected with a low dose of RH (103 parasites)
intraperitoneally and monitored for survival. All mice succumbed to infection by day 8
p.i. B) Using a mutant of ROP16 in RH that reduces virulence and allows the parasite to
form brain cysts, 5 mice per group of control and LysM-cre Stat3fl/fl were infected by oral
gavage with 500 cysts and monitored for survival. A large proportion of both groups
succumbed to infection by around day 15 with a few wild type mice surviving past 20
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days. C-D) 5 mice were group were infected intraperitoneally with 104 Pru (C) or by oral
gavage with 50 cysts of Me49 (D) and monitored for survival. All mice in both groups
survived the duration of the experiment. Results are indicative of two independent
experiments.
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Figure 7. LysM-cre Stat3fl/fl mice have similar levels of IL-12p40 and IFN-γ despite
diminished IL-10 production during acute infection. To determine if proinflammatory responses are heightened in LysM-cre Stat3fl/fl mice, the numbers of PECs
and splenocytes were counted as well as the sera from Stat3fl/fl (n=5) and LysM-cre
Stat3fl/fl mice (n=5) infected for 10 days was analyzed for total cellularity and cytokine
production. A) The total number of cells recovered from the peritoneum of infected mice
was greater in LysM-cre Stat3fl/fl mice although this was not considered statistically
significant. B) The total number of splenic cells of Stat3fl/fl and LysM-cre Stat3fl/fl mice
was comparable at day 10 p.i. C,D) IFN-γ and IL-12p40 concentrations in the sera were
found to be comparable despite lower levels of IL-10. Mean +/- SD. Two independent
experiments were performed with similar results.
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LysM-cre Stat3fl/fl mice have lower parasite burdens despite similar inflammatory
responses during chronic T. gondii infection
To determine if chronic infection was altered in LysM-cre Stat3fl/fl mice, these and
control mice were orally infected with 20 cysts of Me49 and sacrificed at day 43 for
parasite burden and analysis of the inflammatory response. At this time point, there was
significantly lower parasite DNA in the brains of LysM-cre Stat3fl/fl mice than Stat3fl/fl
mice (Figure 8A). Despite this reduction, cysts could still be observed in the brains of
LysM-cre Stat3fl/fl mice while very little pathology was apparent in either genotype
(Figure 8B). This reduced parasite burden was associated with comparable populations
of splenocytes and brain mononuclear populations (Figure 8C). Moreover, there was no
increase in total CD4+ or CD8+ T cells in LysM-cre Stat3fl/fl mice that might explain the
lower parasite burdens (Figure 8E). CD4+ T cells were also similarly activated
(CD62Llow, CD44hi) between Stat3fl/fl and LysM-cre Stat3fl/fl mice (Figure 8F). Moreover,
there was no difference between genotypes for the production of IFN-γ, IL-10, or IL-17
from CD4+ T cells isolated from the brains of infected mice. These data suggest that the
reduction in parasite burdens occurred early during infection and was not due to
enhanced T cell responses.
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Figure 8. LysM-cre Stat3fl/fl mice have similar inflammatory responses yet lower
parasite burdens in the brain during chronic T. gondii infection. To determine if
LysM-cre Stat3fl/fl mice have stronger pro-inflammatory responses following T. gondii
infection, Stat3fl/fl and LysM-cre Stat3fl/fl mice (n=5 per group) were infected with 20 cysts
of Me49 intraperitoneally and sacrificed at day 43 post-infection. A,B) Brain samples
were taken and analyzed for parasite DNA (A) and pathology (B). LysM-cre Stat3fl/fl
mice had significantly lower parasite burdens than control mice despite similar
pathology. Cysts were identified in LysM-cre Stat3fl/fl mice, although rare, indicating that
sterile clearance was not achieved. C,D) Total number of recovered splenic (C) and brain
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(D) cells showed no significant difference between control and LysM-cre Stat3fl/fl mice.
E) There was no difference between control and LysM-cre Stat3fl/fl mice in the total
number of CD4+ and CD8+ T cells in the brain although there is a trend toward fewer T
cells. F) Stat3fl/fl and LysM-cre Stat3fl/fl mice had similar levels of naïve (CD62Lhi,
CD44low) and activated (CD62Llow, Cd44hi) CD4+ T cells at day 43 post-infection. G)
Control and LysM-cre Stat3fl/fl mice had similar numbers of IFN-γ-, IL-10- and IL-17producing CD4+ T cells in the brain during chronic infection.
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Discussion
STAT3 is an important transcription factor involved in numerous signaling
cascades from multiple cytokine and it was shown that T. gondii directly phosphorylates
STAT3 to specifically interfere with macrophage production of IL-12p40 and TNF-α 86,
87, 270

. These studies implied that macrophages were an important cell type in resistance

to T. gondii and that BMMφ were indicative of macrophage/monocyte populations that
the parasite might encounter in vivo. Because STAT3-knockout mice are embryonic
lethal succumbing early during development 279, the ability to make conditional
knockouts of STAT3 in macrophages provided a useful tool to determine the role of
macrophage-specific STAT3 during T. gondii infection.
In contrast to other reports that used human fibroblasts 87, T. gondii induced the
phosphorylation of STAT3 in macrophages independently of genotype. Moreover,
macrophages from LysM-cre Stat3fl/fl mice demonstrated no defect in cytokine production
in vitro. They were able to respond to Pru infection and produce IL-12p40 similarly to
control macrophages and also did not produce TNF-α, IL-6, NO, or the chemokines
CCL3, CCL4, and CCL5 in response to infection with either strain alone. Surprisingly,
STAT3-/- macrophages did not produce enhanced TNF-α or IL-12p40 in response to LPS
stimulation as was hypothesized. Indeed, when LysM-cre Stat3fl/fl mice were infected, no
increase in IL-12 was observed acutely or chronically and there was no difference in
acute parasite burden at the site of infection. There was also no difference in survival for
both RH and Pru infections suggesting that macrophages and neutrophils lacking STAT3
have little difficulty controlling parasite replication. There was, however, a significant
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decrease in parasite DNA in the brains of LysM-cre Stat3fl/fl mice although the presence of
cysts indicates that this was not sterile clearance. It is surprising that despite lower IL-10
levels, no enhanced cytokine production or T cell activation was observed but these
effects may imply that IL-10 cannot act on macrophages to inhibit microbicidal function.
These anti-microbial effects likely occur either in macrophages at the site of
inflammation and these acute effects might be observed prior to day 10 or in the brain
microglia that are assist in controlling chronic parasite burden. Further experimentation
on STAT3 in microglia would determine if these effects contributed to the observed
decrease in parasite DNA in that LysM-cre Stat3fl/fl brains.
While it is not surprising that LysM-cre Stat3fl/fl mice could not resist RH
infection, it is interesting that STAT3 did not have an effect on inflammation in vivo.with
the less virulent Pru given much of the previously reported in vitro data 87, 270. This
indicates that either STAT3 is relatively unimportant in macrophages during infection
because the effects of T. gondii on STAT3 are minimal in vivo, or that macrophages
themselves are not a major source of IL-12. These data suggest that although STAT3 is
upregulated in macrophages by both RH and Pru and this is associated with defective
pro-inflammatory responses, this effect does not translate into a life or death phenotype
potentially because other cell types such as dendritic cells are more important for
cytokine production. It also implies that perhaps CD11c-cre Stat3fl/fl mice may have the
predicted enhanced resistance because it is a more prominent producer of IL-12 during T.
gondii infection. This subject will be discussed in more detail in Chapter V.
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III.

In the absence of SOCS3, IL-6 is a potent inhibitor of
the immune response.
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Abstract
Resistance to Toxoplasma gondii is dependent upon interferon-γ (IFN-γ) signaling
which induces both pro-inflammatory cytokines and effector molecules that allow
infected cells to kill this pathogen. T.gondii has developed multiple mechanisms to evade
this response including the ability to activate STAT3 in host cells that inhibits proinflammatory responses. Suppressor of Cytokine Signaling molecule 3 (SOCS3) is a
protein downstream of STAT3 signaling with multiple inhibitory effects including
limiting IL-6 signaling. The studies presented here reveal that SOCS3 is upregulated in
macrophages following infection with T. gondii and when mice that lack SOCS3 in
macrophage and neutrophil lineages (LysM-cre Socs3fl/fl) were challenged with this
parasite, they succumbed to infection associated with high parasite burdens. This
enhanced susceptibility is not the result of delayed or decreased immune cell recruitment
but is instead due to impaired production of IL-12 and IFN-γ, leading to an inability to
restrain parasite replication. This phenomenon is explained by the observation that
neutralization of IL-6 in LysM-cre Socs3fl/fl mice resulted in improved control of parasite
load and prolonged survival. Together, these data provide direct in vivo evidence that the
ability of SOCS3 to suppress IL-6 signals is essential for resistance to T. gondii.
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Introduction
Toxoplasma gondii is an opportunistic pathogen of patients with a variety of
primary and secondary deficiencies in T cell function 3, 51, 280. Numerous experimental
systems have shown that control of T. gondii is achieved through a combination of innate
and adaptive responses that are dependent upon accessory cell production of IL-12 that
drive natural killer (NK) and T cells to produce IFN-γ 15, 18, 103, 281, 282. These cytokines are
critical for long term-resistance to T. gondii as mice deficient in either IL-12 or IFN-γ
succumb to the acute phase of this infection 15, 18, 103, 281, 282. Secreted IFN-γ stimulates
antigen-presenting cells, including macrophages, to upregulate effector functions that
enhance microbial killing. In current models, the ability of IFN-γ to activate the
transcription factor STAT1 synergizes with factors such as TNF-α, IL-1, and CD40L that
utilize NFκB signaling to promote robust anti-microbial responses 112, 283. Together,
these stimuli induce the expression of numerous genes, such as those that code for
inducible nitric oxide synthase (iNOS) and the Interferon Responsive Gene (IRG) family
of p47 GTPases, that are critical for resistance to T. gondii 284-286.
Similar to many other pathogens, T.gondii has evolved a number of strategies to
evade host anti-microbial activity. For example, multiple groups have provided evidence
that T. gondii can interfere with the activation of NFκB 287-289. Similarly, T.gondii has
been shown to antagonize IFN-γ signaling by inhibiting the phosphorylation of STAT1
and preventing its nuclear translocation and by upregulating SOCS1, a suppressor of
IFN-γ-signaling 290-292. This pathogen has also been shown to interfere with recruitment
of p47 GTPases to the parasitophorous vacuole, thus limiting the ability of IFN-γ62

activated cells to control parasite replication 284, 285, 293. More recent work has highlighted
the role of the transcription factor STAT3 in the ability of T. gondii to evade host
responses 86, 88, 272. Under normal circumstances, STAT3 is activated by a number of
cytokines including IL-6 and IL-10, which have been linked to direct inhibition of antimicrobial effector function as well as enhancement of the growth of pathogens such as T.
gondii, Mycobacterium, and Leishmania species 294-296. Notably, T.gondii injects a
rhoptry kinase, ROP16, that directly phosphorylates STAT3 independently of either IL-6
or IL-10, and this event is associated with impaired IL-12p40 and TNF-α production by
macrophages 86 87, 285. These observations suggest that the ability of T. gondii to directly
activate STAT3 limits anti-microbial responses and promotes parasite survival.
Although STAT3 appears to be a key target of T. gondii during infection, the
downstream effects of STAT3 that promote parasite replication are unclear. One
candidate gene, upregulated by IL-6 and IL-10-mediated activation of STAT3, is
Suppressor of Cytokine Signaling 3 (SOCS3). SOCS3 binds to the granulocyte colonystimulating factor receptor (G-CSFR), the leptin receptor, and also to the gp130 subunit
of the IL-6 receptor complex where it limits IL-6 signaling but does not appear to
interfere with IL-10-mediated events 254, 267, 297-299. In addition, SOCS3 has also been
proposed to limit NFκB signals and to act as an ubiquitin ligase and represents an ideal
candidate to mediate components of the suppressive effects of T. gondii invasion 300, 301.
To investigate if macrophage SOCS3 is involved in the ability of T. gondii to suppress
the immune response, we utilized mice in which the Socs3 gene is flanked by loxP sites
and Cre recombinase is inserted under the control of the Lysozyme M promoter to
specifically delete Socs3 from macrophages and neutrophils (LysM-cre Socs3fl/fl).
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Although SOCS3 was not required for the ability of T. gondii to suppress cytokine
production in vitro, infection of these mice resulted in overwhelming parasite burdens
characterized by impaired neutrophil, monocyte, Natural Killer, and T cell responses and
these animals succumbed acutely to infection. Administration of neutralizing antibodies
to IL-6 blocked disease susceptibility suggesting that in the absence of SOCS3,
macrophages are hypersensitive to the anti-inflammatory properties of IL-6.
IL-6 is a cytokine with many described pleiotropic effects. It has historically been
considered to be pro-inflammatory, having these actions in disease models of arthritis and
asthma 194, 302. There is evidence that IL-6 is required for chronic control from T. gondii
as IL-6-/- mice succumb to chronic infection due to impaired humoral immunity (Silver
unpublished studies) 180, 303. However, IL-6 has anti-inflammatory properties as in vitro
activation and killing by macrophages stimulated with IFN-γ and TNF-α was able to be
impaired in the presence of IL-6 and was true for a number of infectious organisms
including T. gondii, L. braziliensis, and M. avium 294, 296, 304. While IL-6 has antimicrobial responses during T. gondii, this chapter will address the role that IL-6 plays in
inhibiting pro-inflammatory responses and discuss how these actions are exacerbated in
the absence of its negative regulator, SOCS3.
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Materials and Methods
Mice and infections
LysM-cre Socs3fl/fl mice were originally generated by Douglas Hilton and Warren
Alexander as previously described 305. C57/Bl6 mice were obtained from Taconic Farms
Inc (Germantown, NY). C57/Bl6, Socs3fl/fl, and LysM-cre Socs3fl/fl mice were bred in the
University Laboratory Animal Resources facilities at the University of Pennsylvania. All
procedures were performed in accordance to the guidelines of the University of
Pennsylvania Institutional Animal Care and Use Committee. RH and Prugniaud (Pru)
parasites were grown in Human Foreskin Fibroblast (HFF) monolayers cultured with D10
media (DMEM, 25% M199 Supplement, 10% Fetal Bovine Serum, 0.5%
penicillin/streptomycin (10,000 µg/mL), 0.5% gentamycin (50 µg/mL)) and harvested as
previously described 273. Tomato-expressing RH and Pru parasites were grown and
harvested as previously described 275. Bone-marrow derived macrophages (BMMφ) were
flushed from mouse femurs and grown for 6 days in DMEM containing 1% sodium
pyruvate, 1% penicillin/streptomycin, 10% FBS, 30% L929 cell supernatant, and 1%
HEPES 269, 273. All Pru infections were performed i.p. with 104 parasites except for PruTomato where 106 was used. Infection with Me49 was performed with 20 cysts i.p.
Injections of 200 µg of α-IL-6 (BioXCell, West Lebanon, NH) or rat IgG (Sigma, St.
Louis, MO) were administered i.p. at day -1 and 2 post-infection. For vaccination
studies, 5 mice per group were given 106 CPSII parasites intraperitoneally for 7 days
followed by challenge with 104 Pru. Thioglycollate injections were performed i.p. with
0.5 mLs of 4% Brewer’s thioglycollate medium (Sigma) and peritoneal exudates cells
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(PECs) were harvested on day 4 as described 273. 2.5x105 thioglycollate-elicited
macrophages were then plated for 24 hrs in 200 µl total volume and supernatants were
used for detection of IL-12p40 production by ELISA.

Immunoblotting
106 BMMφ were cultured in 96 well plates overnight and then infected with 5:1 Pru
parasites for the indicated durations. Lysates were prepared using TNT buffer (0.1 M
Tris-HCl, pH 7.5, 0.15 M NaCl, and 0.05% Tween 20) combined with complete protease
inhibitors (Roche, Mannheim, Germany) at 1:100 for 20 minutes on ice and then stored at
-20°C. Samples were electrophoresed and transferred to Immobulon-P membrane
(Millipore, Bedford, MA) and blocked for 1 hr in 5% nonfat dry milk and probed
overnight with mouse monoclonal antibodies to SOCS3 (Invitrogen, Carlsbad, CA), βactin, pSTAT3, total STAT3, pSTAT1, total STAT1, pERK, and total ERK (Cell
Signaling, Danvers, MA). Blots were washed in TBS-Tween 3 times and probed with αmouse or α-rabbit secondary antibodies conjugated to horseradish peroxidase (Jackson
ImmunoResearch, West Grove, PA) at 1:10,000 for 1 hr at room temperature. Blots were
washed 3 times and developed with enhanced chemiluminescence and exposed to film.
Results are representative of two independent experiments.

Confocal immunofluorescence microscopy
5x105 BMMφ were isolated and cultured in 96 well plates and infected at a multiplicity of
infection (MOI) of 1:1 Pru parasites. Cells were blocked, fixed with 2%
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paraformaldehyde, incubated with monoclonal α-SOCS3 (Invitrogen) overnight, washed,
and detected by incubation with biotinylated anti-mouse antibodies and streptavidin
conjugated to Alexafluor 488 (Invitrogen) for an additional hr. Cells were then washed,
centrifuged onto slides, and visualized using the Nikon Eclipse E600 microscope
(Melville, NY) equipped with a Photometrics Cool Snap EZ CCD camera (Tucson, AZ).
Results are representative of two independent experiments. Transwell experiments were
performed with a 0.5mM filter. 106 BMMφ were plated onto 12 well plates containing
coverslips. Adjacent wells with cells but without coverslips were infected with parasites
(1:1 M.O.I.) for 60 minutes, loosened with a cell scraper, then transferred to the top of the
transwells over wells with no parasites for 3hrs. After 3 hrs, the transwell was removed
and the coverslips with fixed and stained as described above for other immunofluorescent
studies. Supernatants from these infected cells were taken and layered onto other naïve
cells for 3 hrs to serve as an additional control. These results are not shown but discussed
in the text.

RNA isolation and quantitative Real Time PCR
RNA was isolated using the RNeasy kit (Qiagen) according to manufacturer’s
instructions and reverse transcribed into cDNA using Superscript II (Invitrogen) using
standard protocols. Quantitative PCR was performed with customized primer sets for
Socs3 (Forward 5’-ACCAGCGCCACTTCTTCACG-3’, Reverse 5’GTGGAGCATCATACTGATCC-3’) and Socs1 (Forward 5’ACTTCTGGCTGGAGACCTCA-3’, Reverse 5’-CCCAGACACAAGCTGCTACA-3’)
using Power SYBR green reagents and an AB7500 Fast Real Time PCR thermal cycler
(Applied Biosystems, Warrington UK). The values for Socs3 were normalized to β−Actin
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(Qiagen, Germantown, MD). The arg1 primer set was purchased from Qiagen. Parasite
DNA levels were measured by real time PCR on DNA isolated from the tissue samples
using the High Pure PCR Template Purification Kit (Roche). For measurement of
parasite burden, the 35-fold repetitive T. gondii B1 gene was amplified by real-time PCR
with SYBR Green PCR Master mix (Applied Biosystems) in an AB7500 fast real-time
PCR machine (Applied Biosystems) using published conditions 25. These experiments
were repeated twice with similar results.

Cytokine and flow cytometric analysis
Whole splenocytes were washed and resuspended in complete RPMI 1640 (Invitrogen)
containing 10% FBS (Serum Source International), 1% penicillin/streptomycin
(Invitrogen), 1 mM sodium pyruvate (Mediatech, Manassas, VA), 2 mM L-glutamine
(Mediatech), 0.1% 2-mercaptoethanol (Invitrogen) before being plated at a cell density of
106 cells per well in a final volume of 200 µl in 96-well plates (Costar, New York). Cells
were stimulated with or without soluble Toxoplasma antigen (STAg) at 50 µg/mL, or αCD3 at 1µg/mL (eBioscience) for 24 hr at 37 C in 5% CO2. Peritoneal cells were isolated
as previously described 25 and cell-free peritoneal wash fluid was used for cytokine
analysis. Concentrations were normalized to the amount of peritoneal fluid recovered
from each mouse. Blood was collected via cardiac puncture. Concentrations of IFN-γ,
IL-12p40, and IL-6 were determined by ELISA using antibodies from eBioscience (San
Diego, CA). Freshly isolated PECs from infected mice were incubated with Fc block
(0.1 µg/mL 24G2 antibody) for 15 min prior to surface staining with Ly6C-PerCP 5.5
(HK1.4), CD11b-FITC (M1/70), F4/80-eFluor 780 (BM8), GR1-PECy7 (RB6-8C5),
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CD86-APC (16-10A1), CD80-PE (GL1), NK1.1-PE (PK136), CD4- eFluor. 780 (RM45), CD8-PerCP 5.5 (53-6.7), CD19-PECy7 (eBio1D3 (1D3)), CD11c-APC (N418),
CD62L-APC (MEL-14), and CD44-PE (IM7) (eBioscience, San Diego, CA), MHC Class
II I-A/I-E (Biolegend, M5/114.15.2), CD3ε-Pacific Blue (500A2), and CD19-Pacific
Blue (1D3) (BD Biosciences). For intracellular cytokine staining, 106 PECs were plated
in RPMI 1640 and stimulated with PMA (50 ng/mL) and ionomycin (500 ng/mL) in the
presence of brefeldin A (10 µg/mL) (Sigma) for 4 hrs at 37 °C with 5% CO2 unless
otherwise noted. The cells were fixed with 2% paraformaldehyde following surface stain.
(Electron Microscopy Science, Hatfield, PA) for 10 min. For intracellular staining, the
cells were permeabilized with 0.5% saponin (Sigma, St. Louis, MO) and stained with
anti-IFN-γ-APC (XMG1.2) or IL-12p40-APC (17.8) (eBioscience). All flow cytometry
was performed on a FACSCanto using FACSDIVA 6.0 software (BD Biosciences, San
Jose, CA). Analysis was performed using FlowJo software (Treestar Inc., Ashland, OR).

In vitro killing assay and inhibition assays
5x105 BMMφ were harvested and cultured in 96 well plates and pretreated overnight with
media alone or IFN-γ (BD Biosciences, San Jose, CA) and TNF-α (eBioscience) at
indicated concentrations. Cells were then infected with Pru at 1:1 and incubated
overnight. Cells were then centrifuged onto microscope slides and the number of
infected macrophages was counted. Nitrite analysis was performed using the Griess
protocol. Briefly, 50µl of sample was added to equal volume of a mixture (1:1) of 1%
sulfanilamide and 0.1% naphthylethylenediamine in 2% (vol/vol) phosphoric acid. After
incubation at room temperature, the optical density of the reaction product was measured
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at a wavelength of 540 nm and the nitrite concentration was calculated with sodium
nitrite as a standard. For parasite cytokine-inhibition assays, 2x105 BMMφ were plated
and infected with either RH or Pru parasites at an MOI of 1:1 for 1 hr prior to LPS
stimulation (100 ng/mL, Sigma) for 24 hours. For IL-6 inhibition assays, BMMφ were
stimulated with IFN-γ (10ng/mL) and LPS (10ng/mL) with or without IL-6 (10 ng/mL) at
10 fold increments beginning at 0.001 ng/mL (eBioscience) or α-IL-6 (100 ng/mL,
BioXcell). ELISAs of supernatants from 24 hr cultures were performed using antibodies
for IL-12p40, IL-6, IL-10, and TNF-α (eBioscience). CCL3, CCL4, and CCL5 ELISAs
were performed with DuoSet kits provided by R&D Systems (Minneapolis, MN).

Arginase activity
Arginase activity was performed as described 306. Briefly, 106 BMMφ were plated in
sterile microcentrifuge tubes and stimulated with 40 ng/mL IL-4 (Peprotech, Rocky Hill,
NJ), 10ng/mL IL-10, or infected with RH or Pru (M.O.I. 5:1) for 1 hr. Cells were washed
in PBS and were lysed with 100 µl Triton 100X, and given 50µl of 10 mM MnC12,and
50 mM Tris-HCl, pH 7.5 were added and the enzyme was then activated for 10 minutes
at 55°C. Arginine hydrolysis was performed by adding of 25µL of 0.5 M arginine, pH
9.7 to a 50 µl aliquot of the previously activated lysate. Incubation was per-formed at
37°C for 60 min and the reaction stopped by the addition of 400 µl of an acid mixture
containing H2SO4, H3PO4 and H2O (1:3:7). Urea output was measured the urea
colorimetrically 540 nm.
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Statistical analysis
Statistical analysis was conducted on normally distributed data with Students’ t test or
One-Way ANOVA, and calculated with Prism software (Graphpad Software).
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Results
Toxoplasma gondii upregulates SOCS3 in macrophages.
Previous studies have shown that infection of macrophages with T. gondii in vitro
results in the rapid phosphorylation of STAT3 through a mechanism independent of IL-6
or IL-10 87, 88. Since STAT3 activation is associated with the induction of SOCS3,
experiments were performed to determine if T. gondii infection also led to the
upregulation of SOCS3. Therefore, SOCS3 mRNA and protein were measured in bone
marrow-derived macrophages (BMMφ) (A) and resident peritoneal macrophages (B)
infected with the Type I strain (RH) or a Type II strain (Prugniaud) of T. gondii.
Unstimulated cells had a low basal level of SOCS3 mRNA with no observable SOCS3
protein, while infection with either strain of T. gondii induced a rapid increase in SOCS3
mRNA (Figure 9A,B). SOCS3 mRNA was upregulated following 1 hr of infection and
remained elevated at 3 hrs, an effect that was comparable to that observed following
stimulation with IL-6 (Figure 9B, black bars). SOCS3 protein was also found to be
upregulated following infection with live infection only as macrophages treated with
STAg did not upregulate SOCS3 protein (Figure 9C).
To directly assess if infected cells expressed SOCS3, immunofluorescence was
performed on BMMφ infected for 3 hrs with a transgenic RH parasite that expresses the
fluorescent protein Tomato (RH-Tomato). To confirm specificity, macrophages deficient
in SOCS3 were used and SOCS3 protein was not detected by immunofluorescence in
resting macrophages or those lacking SOCS3 isolated from LysM-cre Socs3fl/fl mice
(Figure 9E). Additionally, SOCS3 mRNA was not observed in SOCS3-deficient
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macrophages infected with either strain of parasite (Figure 9B, white bars). SOCS3
deletions were specific for SOCS3 as T. gondii was still able to induce upregulation of
SOCS1 in peritoneal macrophages (Figure 9D). Additionally, following infection there
was increased SOCS3 expression in wild type cells while fluorescence was absent in
knockout cells (Figure 9E).
The images in Figure 9E revealed that in wild type macrophages, SOCS3 was
upregulated in both infected and uninfected cells. Based on a recent report that T. gondii
can inject rhoptry proteins that influence host cell signaling without directly infecting
them studies were performed to assess whether this phenomena contributed to the
expression of SOCS3 in uninfected cells 307, 308. Therefore, transgenic parasites that
expressed Cre recombinase (Pru-Cre-Cherry and RH-Cre-Cherry) were used to infect
Socs3fl/fl BMMφ for 3 hrs and compared to control parasites containing empty vectors
Pru-PCL1-Cherry and RH-Tomato respectively (Figure 10A,B). If rhoptry proteins are
involved in the upregulation of SOCS3, then the injection of the Cre recombinase should
excise the Socs3 gene and the infection-induced upregulation of SOCS3 typically
observed in these cultures should be reduced. It should be noted here that these effects
were not observed when cells were infected for shorter time points such as 1hr indicating
that there is a lag between the infection and the time required to excise the gene. In
Figure 10A, there is no upregulation of SOCS3 in uninfected cells but a dramatic increase
in SOCS3 expression following infection with the Pru strain expressing an empty vector,
Pru-PCL1-Cherry. However, Pru-Cre-Cherry induced no upregulation of SOCS3 in
either infected or uninfected cells and the brightfield view is shown here to verify
infected cells (Figure 10A). This was also observed in RH-Cre-Cherry-infected cultures
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where no upregulation of SOCS3 was observed (Figure 10B). Additionally, while the
RH-Tomato parasites induced SOCS3 expression in uninfected and infected cells, this
was markedly reduced (by approximately 10 fold, 55% versus 5%) when the RH-CreCherry parasites were used (Figure 10B,C). When supernatants from macrophages
infected with T. gondii were directly added to cultures of uninfected cells this did not lead
to the upregulation of SOCS3 (data not shown) and when infected cells were placed on
the top of a Transwell apparatus, there was no upregulation of SOCS3 in the lower cell
layer (Figure 10A, bottom panels). Together, these data are consistent with a model in
which the ability of the parasite to inject rhoptry proteins into infected and uninfected
cells explains the widespread expression of SOCS3 that we observed.
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Figure 9. T. gondii upregulates SOCS3 in macrophages.
Cultures of macrophages infected with T. gondii demonstrate increases in SOCS3 mRNA
and protein that is correlated with STAT3 phosphorylation and decreased IL-12p40
secretion. SOCS3-deficient macrophages show stronger STAT3 phosphorylation and a
defect in IL-12 production. A,B) 106 BMMφ (A) or resident peritoneal macrophages (B)
from C57/Bl6 mice were infected with RH or Pru at an M.O.I. of 5:1 for the 3 hrs.
Peritoneal macrophages were also stimulated with IL-6 (100 ng/mL) for 3 hrs. RNA was
extracted, reverse transcribed into cDNA and Quantitative Real Time PCR was
performed using SOCS3-specific primers. Results are relative to β-Actin and
representative of two experiments. C) Western blot analysis was performed on lysates of
106 BMMφ infected at 1:1 with RH, Pru, or stimulated with STAg (50 µg/mL) and the
lysates were probed with a SOCS3-specific antibody and compared to β-Actin. D)
Quantitative Real Time PCR was performed with primers specific to SOCS1 and SOCS3
and normalized to β-Actin for SOCS3 and SOCS1 from resident peritoneal macrophages
isolated from naïve control mice, Socs3fl/fl, or LysM-cre Socs3fl/fl mice and incubated with
RH, Pru, or IL-6 (100ng/mL) for 3 hrs. E) BMMφ were infected at 1:1 for 1 hr with RHTomato and then fixed, stained with DAPI and antibodies to SOCS3 conjugated to
Alexafluor 488, and transferred to slides for confocal microscopy.
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Figure 10. Upregulation of SOCS3 by T. gondii requires direct invasion or injection
of parasite proteins.
When macrophages are cultured with either RH or Pru parasites, they upregulate SOCS3
and this is dependent upon injection of parasite proteins presumably secreted rhoptry
proteins. To address this, 5x105 Socs3fl/fl BMMφ that do not express Cre were plated on
coverslips and infected for 3 hours with fluorescent Pru parasites that expressed either cre
recombinase or a control protein or media alone. A) Media alone did not induce
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upregulation while Pru that expressed the control protein (Pru-PC1L-mCherry) strongly
induced the upregulation of SOCS3 (Top, 1st two panels). Incubation with Pru-CremCherry failed to induce the upregulation of SOCS3 in infected or uninfected bystander
cells suggesting that direct infection of the parasite is required for SOCS3 expression.
Transwell experiments were also performed to support this as 5x105 Socs3fl/fl BMMφ on
coverslips on the bottom of the 24 well plates while cells infected for 1 hour were added
to the top of the Transwell for 3 hours. Neither strain of Pru parasite was able to induce
upregulation of SOCS3 in cells that did not directly contact the parasite (A, bottom 2
panels). B) Similar to A), RH-Tomato or RH-Tomato expressing Cre recombinase was
used to infect Socs3fl/fl BMMφ for 3 hours. When the parasite expresses Cre it is unable
to upregulate SOCS3 in neighboring cells demonstrating that direct infection is required.
This is quantified in (C) where the total percentage of SOCS3+ cells is shown. In cells
infected with the control strain of RH, a high percentage of cells are positive for SOCS3
and nearly 3 times as many were currently infected at the time of fixation (C, both
panels). For RH-Tomato-Cre parasites, very few cells are positive for SOCS3 and very
few of these are currently infected suggesting that this low level of SOCS3 is background
upregulation. These data are indicative of two independent experiments and confirm that
direct infection of the cell is required for SOCS3 upregulation.
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LysM-cre Socs3fl/fl macrophages have exaggerated pSTAT3 signaling following infection
and produce less IL-12 when stimulated.
Since it has been shown that the ability of T. gondii to antagonize IL-12p40 and
TNF-α production from LPS-stimulated macrophages is STAT3-dependent, experiments
were performed to determine if this effect was also SOCS3-dependent 270. Infection of
wild type BMMφ resulted in a rapid phosphorylation of STAT3 that starts to decline by 4
hrs and is nearly absent by 24 hrs in SOCS3-sufficient macrophages infected with either
RH or Pru (Figure 11A,B). In SOCS3-deficient macrophages, the infection-induced
phosphorylation of STAT3 is detected at 1 and 4 hrs post infection but remained elevated
for up to 24 hrs. This result was consistent with studies demonstrating IL-6 to have
stronger effects in the absence of SOCS3 252, and suggests that the mechanism utilized by
SOCS3 to limit IL-6-activated STAT3 may also affect STAT3 phosphorylation by T.
gondii (Figure 11A,B). To assess whether the presence of SOCS3 was required for the
ability of T. gondii to limit IL-12p40 production, control or SOCS3-deficient
BMMφ were infected for 1 hr prior to LPS stimulation, and then incubated for 24 hrs
before cytokine analysis. Stimulation of wild type macrophages with LPS resulted in IL12p40 secretion and this was reduced when SOCS3-deficient macrophages were used
(p<0.01) (Figure 11C). Infection with RH or Pru resulted in a significantly reduced
ability of LPS to induce IL-12p40 in wild type and SOCS3-deficient macrophages
(Figure 11C). Together, these findings suggest that infection leads to an upregulation of
SOCS3, but this protein is not required for the ability of T. gondii to impair cytokine
secretion by macrophages.
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Figure 11. LysM-cre Socs3fl/fl macrophages have enhanced pSTAT3 signaling and
decreased pro-inflammatory responses following infection with T. gondii.
SOCS3 is upregulated following infection with T. gondii. In order to determine if
SOCS3 is necessary for STAT3-mediated inhibition of pro-inflammatory responses,
western blot analysis was performed on lysates of 106 BMMφ infected at 1:1 with RH or
Pru for the indicated time points. A) Lysates were probed with pSTAT3 and total STAT3
and compared to β-Actin. These data suggest that in the absence of SOCS3, T. gondii
induces enhanced pSTAT3 signaling. To investigate whether the parasite can still inhibit
pro-inflammatory responses in the absence of SOCS3, 2.5x105 BMMφ were infected for
1 hr prior to stimulation with LPS. C) Supernatants were measured following 24 hrs of
stimulation for IL-12p40. These data indicate that SOCS3 is not required for STAT380

mediated inhibition of pro-inflammatory cytokines. Experiments were performed twice
with similar results. Mean +/- SD. Western blots were performed by Carolyn M. Gray.

81

LysM-cre Socs3fl/fl mice succumb acutely to T.gondii infection with high
parasite burdens.
To assess the possible role of SOCS3 in the response to T. gondii, LysM-cre
Socs3fl/fl and Socs3fl/fl littermate control mice were infected with Pru and the disease
course was monitored. While Socs3fl/fl mice survived infection, LysM-cre Socs3fl/fl mice
were highly susceptible to the acute phase of infection, succumbing by day 10 (Figure
12A). To evaluate parasite replication in these mice, the number of infected cells in the
peritoneal cavity was counted. In Socs3fl/fl control mice, there were few infected cells in
the peritoneal cavity at day 4 with little increase by day 8 (Figure 12B,C). A similar
number of infected cells were observed in the peritoneal cavity of LysM-cre Socs3fl/fl at
day 4 as compared to Socs3fl/fl mice; however, there was a significant increase in parasite
burden by day 8 in the peritoneal cavity of LysM-cre Socs3fl/fl including the presence of
free tachyzoites (bottom right arrow) (Figure 12C). Additionally, following infection
with Pru-Tomato, there was a significantly elevated percentage of Tomato+ infected cells
in the peritoneal cavity in LysM-cre Socs3fl/fl mice that did not vary by cell type (Figure
12D,E). As determined by real-time PCR, there was detectable parasite DNA in the
livers of all mice that was statistically higher in LysM-cre Socs3fl/fl mice than Socs3fl/fl at
day 4 and increased dramatically at day 8 (Figure 12F). Histopathological analysis of
liver and lung sections identified little inflammation in control mice yet showed increased
areas of necrosis (arrows) in the liver and enhanced inflammation in the lung of LysM-cre
Socs3fl/fl mice (Figure 12G). These results suggest that enhanced parasite replication led
to the observed tissue damage.
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Figure 12. LysM-cre Socs3fl/fl mice succumb acutely to T. gondii infection.
Infection of LysM-cre Socs3fl/fl mice leads to acute mortality associated with increased
parasite burden in the peritoneal cavity and liver along with increase pathology in the
liver and lungs. A) Socs3fl/fl (n=5) and LysM-cre Socs3fl/fl (n=5) were infected i.p. with
104 Pru parasites and survival was monitored. Infected mice were also sacrificed on day 8
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to determine parasite burden. B,C) PECs were collected, centrifuged onto slides, and
visualized using light microscopy for the percentage of infected cells. Arrows denote
both intracellular and extracellular tachyzoites although only cells with intracellular
parasites were considered infected. D,E) Socs3fl/fl (n=5) and LysM-cre Socs3fl/fl (n=5) were
infected i.p. with 106 Pru-Tomato parasites and PECs were isolated at day 4 postinfection. The total number of live, Pru-Tomato+ cells was counted using flow cytometry
gated on Tomato+ events from the PE channel. E) From the Pru-Tomato+ cells, the
percentage of positive cells that were monocytes (CD11b+, F4/80+, Ly6C+), neutrophils
(CD11b+, F4/80-, Ly6Clow, GR1+), T cells (CD3+ and CD4+ or CD8+), and NK cells
(CD3+, NK1.1+) were evaluated and depicted. F) DNA was extracted from spleen and
liver tissue from day 8 infected mice (n=5) and analyzed by Real Time PCR for parasite
DNA. G) Livers and lungs of infected (day 8) mice were fixed, sectioned, and imaged
using confocal microscopy. Arrows denote regions of increased pathology. Images and
results are representative of two independent experiments. Statistical values were
determined by Student’s t tests. Experiments were performed twice with similar results.
Mean +/- SD.
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Inflammatory monocytes and neutrophils are activated and recruited to the
site of inflammation.
Several studies have established that inflammatory monocytes and neutrophils are
required for acute resistance to T. gondii 108-110, 309. Phenotypically, inflammatory
monocytes are CD11b+, F480+, Ly6Chi, CD62L+, MHCIIhi, and CCR2+, and are thought
to migrate to primary sites of infection and contribute to the control of T. gondii 109, 309.
To test if the enhanced susceptibility of LysM-cre Socs3fl/fl mice was due to altered
recruitment of these populations, flow cytometric analysis was performed on isolated
peritoneal cells from mice infected for 4 days. While the overall number of peritoneal
cells was similar between Socs3fl/fl control and LysM-cre Socs3fl/fl mice at day 4, there
was a statistically significant increase in recruited cells in LysM-cre Socs3fl/fl mice at day
8 (p<0.05) (Figure 13A). Evaluation of CD3- CD11b+ cells in the peritoneal cavity of
uninfected mice revealed that the majority of these cells possessed a phenotype (F4/80hi,
Ly6Cneg) associated with resident macrophages (Figure 13B, left panel). Also, there was
no difference in the number of resident peritoneal macrophages between control and
LysM-cre Socs3fl/fl mice (data not shown). Upon infection, there was recruitment of
neutrophil (CD11b+, Ly6Clow, F4/80low, GR1hi) and inflammatory monocyte populations
(CD11b+, F4/80hi, Ly6Chi, Figure 13B top right quadrant) to the peritoneal cavity by day
4, but no significant difference in number was observed between Socs3fl/fl and LysM-cre
Socs3fl/fl mice (Figure 13C). Moreover, no significant difference in surface expression of
CD62L, MHCII, CD80, and CD86 was observed between neutrophils or inflammatory
monocytes from LysM-cre Socs3fl/fl and control mice suggesting that these populations
express appropriate levels of surface activation markers (Figure 13D-G). To assess their
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functionality, the ability of inflammatory monocytes and neutrophils to produce IL-12p40
during infection was measured. Critically, there was a significant reduction in the
percentage of IL-12p40+ inflammatory monocyte and neutrophils from LysM-cre Socs3fl/fl
mice at day 4 post-infection (Figure 13H,I). Together, these findings indicate that the
inability of LysM-cre Socs3fl/fl mice to control parasite replication is not a consequence of
a failure to recruit activated neutrophil or inflammatory monocyte populations, but may
in fact be due to the reduced ability of these cells to produce IL-12.

87

88

89

Figure 13. Inflammatory monocytes and neutrophils from LysM-cre Socs3fl/fl mice
are deficient in IL-12 production following infection.
LysM-cre Socs3fl/fl mice show impaired IL-12 production from neutrophil and
inflammatory monocyte populations recruited to the peritoneal cavity following infection.
A) Socs3fl/fl (n=5) and LysM-cre Socs3fl/fl (n=5) were infected i.p. with 104 Pru parasites
and sacrificed at days 4 and 8 post infection and the total number of cells in the peritoneal
cavity was quantified. B,C) Live, singlet, CD19-, CD3-, CD11b+ cells were analyzed for
the surface markers Ly6C and F4/80 to identify inflammatory monocytes
(F4/80hi,Ly6Chi) and neutrophils (F4/80low,GR1+, Ly6Clow) and quantified. D-G)
Monocyte and neutrophil populations were stained for the surface markers of activation
MHC Class II, CD62L, CD80, and CD86 and compared for the overall expression by
MFI. H,I) To determine IL-12 production from these cell types, intracellular cytokine
staining was performed by incubating 106 PECs with BFA and Golgi Stop for 5 hrs,
staining with surface markers for monocytes and neutrophils, fixing with
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paraformaldehyde, staining for intracellular IL-12p40, and analyzing by flow cytometry.
Mean Fluorescence Intensity was calculated and is depicted in red. I) The percentage of
IL-12p40+ inflammatory monocytes and neutrophils are shown. One-Way ANOVA
followed by student’s t test was used to determine statistical significance. Results are
representative of two independent experiments. Mean +/- SD.
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LysM-cre Socs3fl/fl mice have impaired NK and T cell responses.
Since IL-12 is critical for NK and T cell–mediated resistance to T. gondii, these
populations were examined to determine if the loss of SOCS3 in macrophages and
neutrophils affected their ability to produce IFN-γ. At day 4, similar numbers of CD4+,
CD8+, and NK1.1+ cells were observed in Socs3fl/fl control and LysM-cre Socs3fl/fl mice
suggesting that the loss of SOCS3 in macrophages and neutrophils did not impair
recruitment of these populations to the site of infection (Figure 14A). Although there
was no observed difference in the population of naïve CD4+ T cells in LysM-cre Socs3fl/fl
mice, there was a statistically significant decrease in activated CD62Llow, CD44hi CD4+ T
cells (Figure 14B,C). Furthermore, CD4+ T and NK cells from LysM-cre Socs3fl/fl mice
were significantly impaired in their ability to produce IFN-γ at day 4 as compared to
control mice with CD8+ T cells demonstrating the same trend though not statistically
significant (Figure 14D,E). To further evaluate the ability of LysM-cre Socs3fl/fl T cells to
produce IFN-γ, splenic recall assays were performed. Surprisingly, after 24 hrs of
incubation with media alone, αCD3, or STAg, Socs3fl/fl control and LysM-cre Socs3fl/fl
splenocytes from day 4 infected mice produced comparable IL-12p40 and IFN-γ (Figure
14F,G). However, impaired production of secreted IL-12p40 was observed in the
peritoneal lavage fluid at day 4 and a similar trend was observed in the sera (Figure
15A,B). Similar production of IFN-γ protein was observed at days 4 and 8 post-infection
in the serum and peritoneal lavage fluid, suggesting that any defect in the production of
IL-12 by monocytes and neutrophils may only affect the early production of IFN-γ. IL10 concentrations were similar at days 4 and 8 post-infection in the peritoneum
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suggesting that the decreased IL-12 levels are not due to increased IL-10 production
(Figure 15C). Taken together, these findings demonstrate that the reduced ability of the
LysM-cre Socs3fl/fl mice to control growth of T. gondii is associated with an early defect
in the ability to produce sufficient IL-12 at the site of infection.
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Figure 14. LysM-cre Socs3fl/fl mice recruit T and NK cell populations with impaired
IFN-γ-producing capabilities.
T and NK cells traffic to the peritoneal cavity in appropriate numbers by day 4 following
infection of LysM-cre Socs3fl/fl mice yet exhibit a less activated phenotype with decreased
IFN-γ production. Socs3fl/fl (n=5) and LysM-cre Socs3fl/fl (n=5) were infected i.p. with 104
Pru parasites and sacrificed at days 4 and 8 post-infection. A) The total number of NK
(B220-, CD3-, NK1.1+), CD4+ (B220-, CD3+, CD4+), and CD8+ (B220-, CD3+, CD8+) T
cells were determined by flow cytometry. A,B) CD4+ T cells were measured for the
surface markers CD62L and CD44 and (C) quantified for the number of activated
(CD44hi, CD62Llow) and naïve (CD44low, CD62Lhi) cells per mouse. D,E) For
intracellular cytokine staining, PECs were incubated with BFA, Golgi Stop, PMA and
ionomycin for 3 hrs and analyzed for IFN-γ production following surface staining for NK
cells, and CD4+ and CD8+ T cells. F,G) 106 splenocytes were plated from extracted
spleens of infected mice and stimulated with media alone or 50 µg/mL STAg. Levels of
IL-12p40 and IFN-γ were measured by ELISA following 24 hrs of stimulation. OneWay ANOVA followed by student’s t test was used to determine statistical significance.
Results are representative of two independent experiments. Mean +/- SD.
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Figure 15. Infected LysM-cre Socs3fl/fl mice show impaired IL-12 production in the
peritoneal cavity at day 4 post-infection.
Peritoneal lavage fluid from infected LysM-cre Socs3fl/fl mice contains a lower
concentration of IL-12p40 at day 4 that corresponds to a similar trend in sera obtained
from blood. Although IFN-γ production appears normal at day 4, a diminished IFN-γ
response was observed at day 8 in the peritoneal lavage fluid. A,B) Fluid from
intraperitoneal lavage of PECs and serum of infected mice at days 4 and 8 were collected
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and analyzed by ELISA for IL-12p40 and IFN-γ. PEC fluid results are present as
ng/peritoneum which is calculated by multiplying the ELISA concentration (ng/mL) by
the mL quantity of peritoneal lavage fluid (PBS) recovered following centrifugation. C.)
PEC fluid concentrations for IL-10 for the indicated time points. One-Way ANOVA
followed by student’s t test was used to determine statistical significance. Results are
representative of two independent experiments. Mean +/- SD.
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IL-6 blocks IL-12p40 production from macrophages.
One possible explanation for the increased susceptibility of LysM-cre Socs3fl/fl
mice was that SOCS3-deficient macrophages were unable to respond to IFN-γ to control
T. gondii. To test whether SOCS3-deficient macrophages could respond appropriately to
IFN-γ in vitro, BMMφ from Socs3fl/fl and LysM-cre Socs3fl/fl mice were incubated with
TNF-α and IFN-γ overnight and then infected with Pru for 24 hrs. Stimulated Socs3fl/fl
control and LysM-cre Socs3fl/fl macrophages limited parasite replication in a
concentration-dependent manner (Figure 16A,B). To determine if IFN-γ signaling was
impaired in SOCS3-deficient macrophages, cells were incubated with IFN-γ and the
phosphorylation of STAT1 and STAT3 was measured. Unlike control macrophages,
SOCS3-deficient macrophages had abbreviated responses to IFN-γ showing less
phosphorylated STAT1 at later time points (Figure 16C). Additionally, control
macrophages showed an increase in total STAT1 at 20 hrs that was less pronounced in
SOCS3-deficient cells. This observation did not correlate with a reduced ability of the
LysM-cre Socs3fl/fl macrophages to produce nitric oxide (NO), suggesting that this altered
STAT1 signaling pattern did not affect microbicidal activity (Figure 16D). Furthermore,
IRGs are critical to resistance to T. gondii and when their expression was measured in
wild type and SOCS3 knockout BMMφ stimulated with IFN−γ, similar levels of Irgm3,
Irgm1, and Irga6 were detected (Figure 16E). Moreover, peritoneal cells from day 4
infected mice show high levels of Irgm3. They also stain with 3 distinct patterns; small
cells with dense Irgm3 staining that could be neutrophils, large cells with moderate sparse
staining that may be macrophages/monocytes, and small cells with no staining that may
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be T cells (Figure 16F). These populations do not appear different between control and
LysM-cre Socs3fl/fl mice, which along with the immunoblot staining suggest that deletion
of SOCS3 appears to have little impact on the ability of IFN-γ to activate anti-microbial
responses.
IL-6 has been implicated in inhibiting microbicidal killing from activated
macrophages. To test if IL-6 differentially affected LysM-cre Socs3fl/fl macrophages, IL-6
was added to cultures of macrophages stimulated with IFN-γ and LPS. Addition of IL-6
resulted in more infected cells following 24hrs of incubation in wild type and showed a
similar trend in LysM-cre Socs3fl/fl macrophages although not significant (Figure 17A).
These results suggested that IL-6 did not preferentially inhibit microbicidal activity in
LysM-cre Socs3fl/fl macrophages although it could have other consequences of
exaggerated signaling. It was previously reported that deletion of SOCS3 from
macrophages converted IL-6 signals into anti-inflammatory IL-10-like signals due to
enhanced STAT3 activation 252, 310. Indeed, IL-6 induced sustained phosphorylation of
STAT1 and STAT3 in LysM-cre Socs3fl/fl macrophages as compared to Socs3fl/fl
macrophages, yet demonstrated similar kinetics of activation of the MAP kinase ERK
suggesting that only STAT signaling is altered in these macrophages (Figure 17B,C) 311.
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Figure 16. The effects of SOCS3 on IFN-γ signaling in LysM-cre Socs3fl/fl
macrophages do not affect microbicidal function. SOCS3-defiicent macrophages do
not display impaired microbicidal activity, nitrite production, or IRG expression despite
altered IFN-γ-mediated phosphorylation of STAT1. A,B) 5x105 BMMφ were plated and
infected with Pru (MOI 1:1) for 24 hrs following overnight stimulation with TNF-α (10
fold dilutions, beginning at 100 Units/mL) and IFN-γ (10 fold dilutions, beginning at 100
Units/mL). C) Supernatants from (A) were measured for nitrite (nitric oxide) production
following the Griess reaction protocol. D,E) 106 BMMφ were treated with IFN-γ (100
Units/mL) for the indicated time points and analyzed by western blot for pSTAT1,
IRGM1, IRGM2, IRGM3, IRGD, IRGA6, and IRGB6. F) 106 peritoneal cells from
control and LysM-cre Socs3fl/fl infected with Pru for 4 days were plated on coverslips and
stained for Irgm3 and visualized as described in the methods. Western blots were
performed by Carolyn M. Gray.
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Figure 17. IL-6 does not have altered signaling effects in LysM-cre Socs3fl/fl
macrophages. In order to determine if IL-6 has signaling differences in the absence of
SOCS3, wild type and SOCS3-deficient macrophages were analyzed for the ability of IL6 to prevent microbicidal activity as well as to signal through STAT1, STAT3, and ERK.
A) 106 BMMφ were infected with 1:1 Pru for 24 hours in the presence of IFN-γ/LPS with
or without IL-6 (100ng/mL). B,C) 106 BMMφ were stimulated with IL-6 (100 ng/mL) for
the indicated time points and analyzed for pSTAT3, pSTAT1, and pERK and compared
to β-actin, total STAT3, and total ERK. Error bars +/- SD. Statistics was performed using
Student’s t tests and results are representative of two independent experiments. Western
blots were performed by Carolyn M. Gray.
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IL-6 has specific inhibitory effects on macrophages
IL-6 was shown to have inhibitory functions on macrophage killing abilities but
these effects were not exacerbated by the absence of SOCS3. To determine if IL-6 had
other effects that were enhanced when SOCS3 was deleted, BMMφ were evaluated for
their ability to produce pro-inflammatory cytokines in the presence of IL-6. When cocultured with IFN-γ and LPS, IL-6 was shown to inhibit IL-12p40 production in a
concentration-dependent manner (Figure 18A). Additionally, LysM-cre Socs3fl/fl
macrophages produced significantly less IL-12p40 that control macrophages and this
initial defect could be restored when neutralizing antibodies to IL-6 were administered to
the cultures (Figure 18B). These data indicate that endogenous IL-6 produced in these
cultures acts as an inhibitor of IL-12 and TNF-α (Figure 18B,C). Since IL-6 affects IL-12
and TNF-α, other effects of IL-6 signaling were tested. Nitrite production was found to
be unaffected by IL-6 when IL-6 was co-cultured with IFN-γ and LPS (Figure 18D).
Arginase is an enzyme that inhibits iNOS-mediated NO production by competing
for available arginine stores. Arginase I (Arg1) has also recently been linked to IL-6
activity and it was suggested that this enzyme might play a role in macrophage signaling
and inhibition of microbicidal function. To test if Arg1 was differentially regulated by
IL-6 or T. gondii, mRNA levels were measured from BMMφ after 1 hr of incubation.
LysM-cre Socs3fl/fl macrophages were shown to express less Arg1 mRNA than control
macrophages and these levels were unaffected by either infection or IL-6 stimulation
(Figure 18E). Conversely, when arginase activity was measured as consequence of urea
output in the presence of arginine, LysM-cre Socs3fl/fl macrophages had a higher baseline
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of activity than control macrophages (Figure 18F). Moreover, addition of IL-4 increased
the activity of arginase in both control and LysM-cre Socs3fl/fl macrophages as expected,
and treatment with IL-6, IL-10 or infection with RH or Pru induced similarly higher
levels in LysM-cre Socs3fl/fl macrophages than control macrophages (Figure 18F). These
increased levels more likely reflect the difference in baseline arginase activity and not a
differential effect of the stimuli in LysM-cre Socs3fl/fl macrophages. Overall, it appears
that LysM-cre Socs3fl/fl macrophages may have increased arginase activity relative to
mRNA expression, although without a phenotype of impaired microbicidal activity or
NO production, it is difficult to ascertain the biological significance of these findings.
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Figure 18. IL-6 specifically inhibits IL-12 and TNF-α production from stimulated
macrophages. SOCS3 has been described to limit IL-6 signals. Therefore, the ability of
LysM-cre Socs3fl/fl macrophages to produce pro-inflammatory cytokines in the presence
of IL-6 was evaluated. A) The ability of IL-6 to inhibit IL-12p40 production was
evaluated by stimulating 2x105 BMMφ with IFN-γ and LPS (10 Units/mL and 10 ng/mL
respectively) with or without increasing concentrations of IL-6 (0.001 to 10 ng/mL, 10
fold dilutions) for 24 hrs and analyzed by ELISA. B,C) 2x105 BMMφ were given IFN-γ
and LPS with or without α-IL-6 and analyzed for IL-12p40 and TNF-α production. D)
Similar to (A), nitric oxide was measured from stimulated control and LysM-cre Socs3fl/fl
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macrophages in the presence of increasing concentrations of IL-6. E) mRNA was
measured from 106 BMMφ stimulated with IL-6 or infected with either strain of parasite
for 60 min. F) Arginase activity was measured as Urea output as described in the
Methods section for the indicated conditions and light was measured at 540 nM and set to
relative units. Statistics were performed using Student’s t tests and results are
representative of two independent experiments. Mean +/- SD.
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Neutralization of IL-6 restores the immune response to T. gondii in LysMcre Socs3fl/fl mice
The data described above indicate that, consistent with previous studies, in the
absence of SOCS3 IL-6 becomes a potent antagonist of IL-12 production. To directly test
whether endogenous IL-6 contributed to the observed susceptibility of LysM-cre Socs3fl/fl
mice, Socs3fl/fl and LysM-cre Socs3fl/fl mice were treated with neutralizing antibodies to
IL-6. When these mice were evaluated for survival, control mice given the α−IL-6
treatment survived up to 40 days after challenge (Figure 19A) whereas LysM-cre Socs3fl/fl
mice treated with rat IgG succumbed acutely to T.gondii. However, when these mice
were treated with α−IL-6, 80% of the mice survived acute challenge and progressed into
the chronic phase of this infection (Figure 19A). Analysis of treated mice revealed that
addition of α−IL-6 resulted in a marked reduction in the number of infected cells in the
peritoneal cavity at day 8 in Socs3fl/fl and LysM-cre Socs3fl/fl mice (p<0.001, Figure 19B).
Similarly, IL-6 and IFN-γ levels were significantly decreased in the peritoneum of
Socs3fl/fl and LysM-cre Socs3fl/fl mice (p<0.001) at day 4 post-infection with trends
towards a similar decrease in IL-12p40, IL-10, and IL-17 (Figure 19C-G). No difference
in IL-12p40, IFN-γ, or IL-10 could be detected in the sera at day 4 (Figure 19H-J). A
reduction in cytokine production was observed following α-IL-6 treatment that is likely
the direct result of an overall decrease in cellular recruitment and specifically CD4+ and
CD8+ T cell and to the peritoneal cavity associated with reduced parasite burdens (Figure
19K-M). There was also a decrease in the total number of IFN-γ-producing T cells
(Figure 19L,M) as well as a trend towards fewer IL-12p40- and TNF-α-producing
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monocytes and neutrophils following α-IL-6 treatment (Figure 19N,O). These data
provide evidence that overall inflammation and parasite burdens are reduced following αIL-6 treatment.
Given the reduced inflammation following α-IL-6 treatment, it is difficult to
determine if this antibody treatment restores IL-12 production using an infectious model.
Therefore, to confirm that neutralizing IL-6 in vivo elicits better IL-12 responses, a noninfectious model using thioglycollate macrophages was used. When LysM-cre Socs3fl/fl
mice were given rat IgG, isolated thioglycollate-elicited macrophages from the peritoneal
cavity demonstrated impaired IL-12p40 and TNF-α production as compared to control
mice (Figure 20A,B). This effect was reversed when these mice were treated with
neutralizing antibodies to IL-6. Overall, these data suggest that IL-6 is an inhibitor of
inflammatory macrophages responses during toxoplasmosis and that LysM-cre Socs3fl/fl
mice are hypersensitive to these effects.
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Figure 19. Administration of neutralizing antibodies to IL-6 reduces parasite
burdens and overall inflammation in LysM-cre Socs3fl/fl mice.
In vivo neutralization of IL-6 reduces acute mortality of infected LysM-cre Socs3fl/fl mice
that correlates with reduced parasite burdens and indicators of Th1 inflammation. (A-D)
200 µg/mouse of rat IgG or α-IL-6 was administered i.p. to 5 mice per group on the day
preceding infection as well as 2 days post infection with 104 Pru parasites. (A) Mice were
sacrificed at day 8 p.i. and analyzed for IL-6 by ELISA to confirm neutralization. (B)
Survival of infected mice was performed on 5 mice per group and carried out to 40 days.
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(C) The percentage of infected cells in the peritoneal cavity was measured similarly to
Figure 2C and described in the methods. (D) IL-12p40 and IFN-γ production was also
measured in the peritoneum as described in Figure 5 and the methods. (E) Thioglycollateelicited macrophages were used to determine if a-IL-6 treatments could restore IL-12
production from LysM-cre Socs3fl/fl macrophages. IL-12p40 was measured by ELISA
from 24 hr cultures of 2.5x105 thioglycollate-elicited macrophages isolated from the
peritoneal cavity on day 4 following the antibody regimen described above. Experiments
were repeated twice. One-Way ANOVA followed by student’s t test was used to
determine statistical significance.
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Figure 20. Neutralizing antibodies to IL-6 restores pro-inflammatory function of
thioglycollate-elicited macrophages in LysM-cre Socs3fl/fl mice. Inflammatory
monocytes and neutrophils demonstrate a defect in production of IL-12p40 and TNF-α.
To determine if this effect can be restored in vivo with when IL-6 is blocked,
inflammatory macrophages were elicited with thioglycollate (n=3 per group). A,B) After
4 days, peritoneal cells were isolated and plated for 24 hours and measured for IL-12p40
and TNF-α. While blocking IL-6 had little effect on macrophages elicited from control
mice, it significantly enhanced the ability of macrophages from LysM-cre Socs3fl/fl mice
to produce IL-12p40 and demonstrate a trend, though not statistically significant, towards
restoration of TNF-α production. These data indicate that IL-6 blocks pro-inflammtory
responses from macrophages in vivo. Results are indicative of two experiments. Mean +/SD.
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Neutralizing antibodies to IL-10R reduces parasite burden and inflammation
in LysM-cre Socs3fl/fl mice
Neutralizing antibodies to IL-6 enhance anti-parasitic mechanisms by preventing
IL-6 from inhibiting IL-12 production from macrophages and neutrophils. IL-10 is
another cytokine that signals through STAT3 and has significant inhibitory functions on
APCs 268, 269. To determine if blocking IL-10 signaling would induce a similar reduction
in parasite replication as IL-6, Socs3fl/fl and LysM-cre Socs3fl/fl mice were infected with
Pru and treated with α-IL-10Rα antibodies the day before and two days following
infection. At day 8 post-infection, the total number of PECs demonstrated a trend
towards fewer inflammatory cells following α-IL-10Rα treatment although this was not
significant (Figure 21A). In control mice, there was a moderate reduction in the number
of infected cells in the peritoneum following treatment (Figure 21B). However, there
were significantly fewer infected cells in LysM-cre Socs3fl/fl mice given α-IL10Rα (p<0.001) that was associated with fewer CD4+ and CD8+ T cells in control mice
with a similar trend in LysM-cre Socs3fl/fl mice (Figure 21C). To determine if proinflammatory cytokines were enhanced following α-IL-10Rα treatment, IL-12p40 and
IFN-γ were measured from the sera of day 7 infected Socs3fl/fl and LysM-cre Socs3fl/fl
mice. While IFN-γ levels were unaffected by treatment with α-IL-10Rα, IL-12p40 levels
were enhanced in the sera of LysM-cre Socs3fl/fl mice (p<0.05) with a similar trend in
control mice (Figure 21D,E). Curiously, blocking the IL-10R also increased the IL-10
that could be detected in the sera (Figure 21F). The most likely explanation for the
observed increase in IL-10 is that blocking the IL-10R prevents IL-10 from being
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endocytosed by cells therefore increasing its concentration in the sera. However, overall
these data demonstrate that treatment with α-IL-10Rα reduce parasite burdens and
inflammation in both control and LysM-cre Socs3fl/fl mice.
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Figure 21. Neutralization of IL-10 signaling significantly reduces parasite burden
and inflammation in LysM-cre Socs3fl/fl mice. Addition of blocking antibodies to IL-6
rescues lethality in LysM-cre Socs3fl/fl mice. To determine if this effect could be
reproduced using neutralizing antibodies another inhibitory cytokine, IL-10, that also
signals through STAT3, infected control and LysM-cre Socs3fl/fl mice were treated with αIL-10Rα antibodies. Treated and untreated mice were then evaluated for parasite burden
and markers of inflammation. A) LysM-cre Socs3fl/fl mice recruited a similar number of
cells to the peritoneum as Socs3fl/fl mice at 7 days post-infection and these numbers were
reduced following treatment with α-IL-10Rα. B) The number of infected cells was
significantly greater in untreated LysM-cre Socs3fl/fl mice than Socs3fl/fl mice (p<0.001)
following infection. Upon treatment with α-IL-10Rα, there was a slight reduction in
infected cells in Socs3fl/fl mice and a large reduction in the number of infected cells in
LysM-cre Socs3fl/fl mice (p<0.001). C) This reduction in parasite load corresponded with a
decrease in the number of CD4+ and CD8+ T cells in the peritoneum of Socs3fl/fl mice and
a similar trend in LysM-cre Socs3fl/fl mice. D-F) Concentrations of IL-12p40, IFN-γ, and
IL-10 were measured from the sera of day 7 infected mice. Following treatment with αIL-10Rα, there was a significant increase in IL-12p40 in the sera from LysM-cre Socs3fl/fl
mice with a similar trend in Socs3fl/fl mice. IFN-γ levels remained similar following
treatment and there was an increase in detectable IL-10, although this was not statistically
significant.
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Addition of IL-12 rescues lethality in LysM-cre Socs3fl/fl mice
LysM-cre Socs3fl/fl mice succumb to infection from T. gondii infection associated
with diminished IL-12 production by macrophages and neutrophils. To determine if
LysM-cre Socs3fl/fl mice could survive challenge when provided with exogenous IL-12,
mice were infected and given 200 ng of IL-12 i.p. for 5 days. By day 7, untreated LysMcre Socs3fl/fl mice were moribund and one had died while all control mice and treated
LysM-cre Socs3fl/fl mice did not show the effects (Figure 22A). Untreated LysM-cre
Socs3fl/fl mice had significantly higher parasite burdens and these were associated with an
8% loss in body weight while IL-12-treated LysM-cre Socs3fl/fl mice appeared healthy and
lost significantly less weight by day 6 (Figure 22B,C). Addition of IL-12 reduced
parasite burden and prevented the loss of body weight in LysM-cre Socs3fl/fl mice (Figure
22B,C) Further analysis on days 4 and 7 showed that IL-12 treatment resulted in a
dramatic reduction in parasite DNA in the liver compared to untreated LysM-cre Socs3fl/fl
mice (Figure 22D). While the overall numbers of spleen and PECs were unaffected by
IL-12 treatment, there was a significant reduction in the number of CD4+ cells following
treatment with a similar trend in decreased CD8+ T cell, NK cell, neutrophil, and
monocyte populations in the peritoneum at day 4 (Figure 22E-G). This reduction of
cellularity was associated with a similar trend in IFN-γ, IL-12p40, IL-6, IL-10, and IL-17
production in the peritoneum although these levels were not statistically significant
(Figure 22H). IL-12p40 and IFN-γ levels were significantly decreased in the sera
following IL-12 treatment (Figure 22I) indicating that treatment of infected LysM-cre
Socs3fl/fl mice with IL-12 is sufficient to reduce parasite burden and overcome the
inhibitory actions of IL-6.
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Figure 22. Addition of IL-12 early during T. gondii infection reduces parasite
burden and overall inflammation. In order to determine if addition of IL-12 during
acute infection could rescue lethality, control and LysM-cre Socs3fl/fl mice were infected
with Pru and given PBS or IL-12p70 (200µg/mouse) every day for the first five days for
survival and for days 0-3 for analysis of day 4 infected animals. A) Untreated LysM-cre
Socs3fl/fl mice were moribund on day 7 post-infection with one mouse succumbing to
infection. All other groups appeared normal and showed no signs of clinical TE. B)
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Addition of IL-12 was associated with significantly decreased numbers of infected cells
in the peritoneal of both control and LysM-cre Socs3fl/fl mice. C) IL-12 addition also
resulted in a significant loss of weight by day 6 post-infection in LysM-cre Socs3fl/fl mice
(p<0.05). D) Addition of IL-12 reduced the parasite burden in the livers of LysM-cre
Socs3fl/fl mice at day 4 and day 7 post-infection despite no change in overall PEC and
spleen numbers (E). This decrease in parasite burden was associated with diminished
inflammation. CD4+ T cells were fewer in IL-12-treated LysM-cre Socs3fl/fl mice (F) and
a trend toward fewer CD8+, neutrophils, inflammatory, monocytes, and NK cells
although not statistically significant (F,G). Addition of IL-12 also reduced IFN-γ and IL12p40 levels in the sera with trends towards lower concentrations of IL-12p40, IFN-γ, IL6, IL-10, and IL-17 in the peritoneum and sera (H,I).
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Vaccination can rescue lethality in LysM-cre Socs3fl/fl mice
LysM-cre Socs3fl/fl mice succumb to T. gondii infection associated with large
parasite burdens as a result of impaired IL-12 responses. Both IL-10 and IL-6 inhibit IL12 production from macrophages and removal of the ability of these cytokines to function
restores protective responses and reduces parasite burdens. Addition of IL-12 also
protects LysM-cre Socs3fl/fl mice indicating that SOCS3 is an important regulatory protein
that prevents the inhibition of IL-12 by IL-6 specifically. To better understand how
SOCS3 in macrophages promotes a protective response, Socs3fl/fl and LysM-cre Socs3fl/fl
mice were vaccinated with a replication-deficient strain of T. gondii, CPSII for 1 week
prior to challenge with Pru. As expected, control mice survived challenge out to 25 days
while LysM-cre Socs3fl/fl mice succumbed to infection by day 10 (Figure 23A).
Vaccination of LysM-cre Socs3fl/fl mice, however, resulted in protection from acute
susceptibility by T. gondii. This suggests that while IL-12 production is required for
acute protection in LysM-cre Socs3fl/fl mice, these mice can be primed through other
mechanisms such a humoral responses to promote resistance.
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Figure 23. Vaccination with a replication deficient strain of T. gondii protects
LysM-cre Socs3fl/fl from lethal challenge. To determine if LysM-cre Socs3fl/fl mice can
be primed to resist lethal challenge, control and LysM-cre Socs3fl/fl mice (n=5) were
infected with 106 CPSII parasites for 1 week prior to infection with 104 Pru and
monitored for survival out to 25 days post-infection (A). This experiment was repeated
twice with similar results.
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Discussion
Several reports have highlighted the ability of T. gondii to induce the
phosphorylation of STAT3 in macrophages and that this is associated with the ability to
suppress the production of TNF-α and IL-12

87, 270

. More recently this phenomena has

been linked to the activity of a parasite kinase, ROP16, that is injected into the host cell
cytoplasm and which can directly phosphorylate STAT3 and leads to its activation

86, 87

.

How infection-induced STAT3 activation limits cytokine production remains unclear but
the observation that T. gondii also upregulates SOCS3, a well characterized target of
STAT3 linked to inhibition of cytokine signaling, suggested that this may be part of the
mechanism that allows this pathogen to suppress cytokine production. However, in vitro
studies revealed that SOCS3 was not required for the ability of T. gondii to limit
macrophage production of cytokines. Rather, these in vivo studies using the LysM-cre
Socs3fl/fl mice revealed that SOCS3 was essential for the innate response required for the
initial control of T. gondii. In these mice, the LysM promoter drives expression of Cre
recombinase in neutrophils and monocytes/macrophages, two cell types that have major
roles in the early response to T. gondii 108, 109, 309. These two populations represent a major
source of cytokines early in infection and in the absence of SOCS3 this acute response
was severely compromised and associated with an inability to control T. gondii.
While relatively few studies have addressed the role of SOCS3 in resistance to
infection, the ability of this protein to limit cytokine signaling through the receptor gp130
has been described in detail and is reviewed elsewhere
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. Thus, while many cytokines,

such as IL-6 and IL-10 can activate STAT3 and upregulate SOCS3, this inhibitory
protein binds directly to the gp130 subunit of the IL-6 receptor complex but not the IL125

10R and so SOCS3 acts to inhibit IL-6 but not IL-10 signaling

267, 313

. However, data

presented here show that the absence of SOCS3 resulted in enhanced T. gondii-induced
STAT3 signaling. This suggests that either the ROP16 secreted by T. gondii following
infection associates with the gp130 subunit and is inhibited by SOCS3 similarly to an IL6 stimulus or that SOCS3 has an additional mechanism to limit phosphorylation of
STAT3. Thus, the ROP16-mediated mechanism by which T. gondii activates STAT3 may
be more complex than just direct phosphorylation of this substrate.
The significance of the specific inhibitory action of IL-6 has been highlighted in
multiple reports that in the absence of SOCS3, IL-6 provides a sustained STAT3 signal
that mimics effects observed with IL-10 and that IL-6 now becomes a potent inhibitor of
macrophage production of TNF-α and IL-12

87, 270, 313

. Furthermore, α-IL-6 added to

cultures of stimulated SOCS3-deficient stimulated macrophages completely restored IL12p40 production, enhancing the level of secreted cytokine over IFN-γ/LPS stimulation
alone. This implies that the endogenous IL-6 produced is an antagonist in these cultures.
Consistent with this observation, the neutralization of IL-6 in the LysM-cre Socs3fl/fl mice
allowed these mice to control the acute challenge with T. gondii and develop the
protective responses required for long-term resistance to this infection. Thus, it appears
that in the absence of SOCS3, early IL-6 produced during toxoplasmosis has a profound
inhibitory effect on the acute innate responses. This observation is consistent with
another report in which LysM-cre Socs3fl/fl mice treated with a lethal dose of LPS had
limited TNF-α production and survived the sepsis caused by excessive inflammation 267.
One of the themes that emerged from these studies was that IL-6, even in wild
type cells, has significant but specific inhibitory effects. For example, when wild type
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macrophages were treated with IL-6, their ability to produce IL-12p40 was selectively
inhibited in a dose-dependent manner while other inflammatory molecules such as nitric
oxide were unimpaired. Additionally, when control mice were treated with neutralizing
antibodies to IL-6, their ability to control early parasite replication was enhanced
suggesting that IL-6 is a natural inhibitor of the innate mechanisms that contribute to
early control of T. gondii. Indeed, similar to the studies presented here, the use of
monoclonal antibodies to neutralize IL-6 in chronically infected wild type mice resulted
in improved control of T. gondii but the basis for this effect was not understood 180. IL-6,
similarly to IL-10, can antagonize the ability of IFN-γ-activated macrophages to limit the
intracellular replication of T. gondii, L. amazonensis, and M. tuberculosis and this effect
seems to be exacerbated in the absence of SOCS3

294, 296, 304

. Thus, based on the in vitro

studies, the ability of IL-6 to antagonize the anti-microbial effects of IFN-γ might have
explained how despite high systemic levels of IFN-γ during infection, LysM-cre Socs3fl/fl
mice were unable to control parasite burdens because their macrophages and neutrophils
were unable to respond properly to IFN-γ. Moreover, the observation that the percentage
of macrophages and neutrophils infected with T. gondii is identical between control and
LysM-cre Socs3fl/fl mice indicates that the absence of SOCS3 does not result in a cell
intrinsic defect in the ability to control T. gondii. Together, these data suggest that
SOCS3-deficient macrophages can control parasite replication adequately when provided
the proper signals and that the enhanced susceptibility observed in the absence of SOCS3
is a consequence of altered innate responses.
While this study has focused on the contribution of IL-6 to the regulation of
inflammatory responses during toxoplasmosis, this cytokine is also important in many
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other infectious settings. As previously mentioned, IL-6 promotes growth of Leishmania,
T. gondii, and Mycobacterium spp.

294-296, 304

and human IL-6 has also been shown to be

associated with both enhanced lytic replication of Human Herpes Virus-8 (HHV-8) and
exacerbated disease of patients co-infected with HIV

314

. Also, HHV-8 encodes a viral

IL-6 gene that has been shown to impair neutrophil recruitment and promote viral growth
in vitro 315, 316. Together, these studies highlight how multiple infectious agents can utilize
this pathway to promote their own survival by affecting inflammatory signals. From a
host perspective, resistance to many pathogens is characterized by the need to balance the
development of a strong cell mediated immune response with the ability to limit
collateral damage caused by the immune system.

Indeed, there are many examples of

inhibitory cytokines such as IL-10, TGF-β, and IL-27 that are essential to inhibit
infection-induced immune hyperactivity 22, 25, 317 and the SOCS proteins also limit signals
that promote excessive inflammation. SOCS1 is best described as a regulator of Type I
and II IFN-mediated phosphorylation of STAT1

318, 319

and has been shown to diminish

IFN-γ responsiveness to T. gondii,, L. major, and Hepatitis C Virus 290, 320-322. However,
while SOCS3 may have a role in limiting IFN responses, its main role during T. gondii
infection, and possibly other intracellular pathogens, is to limit the anti-inflammatory
actions of IL-6 including its ability to antagonize IL-12 production.

Thus, SOCS3

differentiates itself from other SOCS family members and its signaling pathway can be
considered among those that promote proper and effective Th1 immunity.
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Chapter IV.

T. gondii structural proteins such as PHIL1 and AMA1
affect the speed of parasite invasion leading to increased
recognition by the immune system.
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Abstract
The inner membrane complex (IMC), a series of flattened vesicles at the
periphery of Apicomplexan parasites, is thought to be important for parasite shape,
motility and replication, but only a few of the proteins that associate with the IMC and
function in these processes have been identified. TgPHIL1 and AMA1 are two such
proteins. TgPHIL1, a Toxoplasma gondii protein, associates with the IMC and/or
underlying cytoskeleton and is concentrated at the apical end of the parasite while Apical
Membrane Antigen 1 (AMA1) is a microneme protein thought to also be involved in
motility and invasion. Orthologs of both proteins are found in other Apicomplexans, but
their functions are largely unknown. TgPHIL1 knockout parasites have a distinctly
different morphology than wild-type parasites, and normal shape is restored in the
knockout background by expression of the wild-type allele. The knockout parasites are
outcompeted in tissue culture by parasites expressing functional TgPHIL1, and the
knockouts generate reduced parasite loads in the spleen and liver of infected mice.
Conditional deletion of AMA1 reduces fitness in vitro and also leads to impaired growth
and enhanced host microbicidal activity in vivo. These findings demonstrate a role for
both AMA1 and TgPHIL1 in the morphology, growth and fitness of T. gondii
tachyzoites.
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Introduction
The Phylum Apicomplexa contains a number of medically important parasites
including Cryptosporidium spp., which cause diarrheal illness in children and immunocompromised patients, Plasmodium spp., which are the causative agents of malaria, and
T. gondii, which causes life-threatening disease in immuno-compromised individuals and
the developing fetus. Although these organisms have been studied for decades, much of
their basic biology is unknown despite their significance to human and veterinary disease.
Because T. gondii is easily grown and is genetically tractable, it provides a robust tool
that allows for study of many aspects of Apicomplexan biology.
One unique feature of the Apicomplexans is the presence of an inner membrane
complex (IMC) which is located beneath the plasma membrane of the parasite. The IMC
is a series of flattened vesicles that comprise the pellicle along with the IMC. Directly
beneath the IMC is an intertwining series of intermediate filament-like proteins called the
subpellicular network 323, 324. Various functions for the IMC and the subpellicular
network have been suggested 323. During parasite replication, the IMC forms early and
may provide a scaffold for tachyzoite assembly or possibly to stabilize mature
tachyzoites. Additionally, some components of the myosin motor complex, necessary for
motility and invasion, are anchored in the IMC 325. Localization of the motor complex
between the outer membrane of the IMC and the plasma membrane is thought to be
critical for motility and invasion. While one member of the myosin motor complex,
GAP45/70, appears to physically connect the IMC to the plasma membrane, the detailed
mechanism by which the IMC, subpellicular network and subpellicular microtubules
associate with each other and are organized within the pellicle have yet to be identified
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326

.
TgPHIL1 (Photosensitized INA-Labeled protein 1) was previously reported to

localize to the parasite periphery, and remain concentrated at the apical end directly
posterior to the conoid, a cone-shaped structure composed of a novel polymeric form of
tubulin 63. TgPHIL1 is highly conserved among members of the phylum Apicomplexa
but demonstrates little homology to proteins in other phyla. When parasites were treated
with Clostridium septicum alpha-toxin, which causes the plasma membrane to swell away
from the IMC, TgPHIL1 remained associated with the IMC and/or associated
cytoskeletal structures 63. Although TgPHIL1 labeling with INA suggests this protein is
membrane associated, TgPHIL1 is also highly insoluble and extracts much like a
cytoskeletal protein 63. In order to identify the function of TgPHIL1, parasites containing
a TgPHIL1 deletion were generated. Phenotypic analysis of the knockout parasites
revealed that TgPHIL1 is necessary for maintaining the distinctive shape of T. gondii
tachyzoites, and parasites lacking TgPHIL1 show both a growth defect in culture and
reduced fitness in a mouse model of infection (Barkhuff, in press).
Similar to TgPHIL1, Apical membrane antigen-1 (AMA1) is a microneme protein
that is highly conserved among Apicomplexan parasites and seems to be involved in
parasite motility and invasion 327, 328. Since its initial discovery 15 years ago, AMA1 has
received considerable attention as a malaria vaccine candidate 329-331. AMA1 proteins are
transmembrane proteins, with a short C-terminal cytoplasmic tail and a large N-terminal
extracellular domain 327, 329-332. Like other microneme proteins, AMA1 is secreted onto
the parasite surface, where its ectodomain is proteolytically cleaved and shed 64, 327, 333.
Additonally, antibodies against AMA1 inhibit invasion of apicomplexans supporting a
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role for this protein in motility and dissemination

67, 327, 334-336

.

Deletion of AMA1 from T. gondii renders the parasite unviable and unable to
replicate 337. Therefore, the development of a system for conditional gene expression in T.
gondii has made it possible to study the function of AMA1 by reverse genetics 338. The
Ward laboratory generated a conditional mutant of AMA1 where the protein is repressed
following tetracycline treatment in vitro or when tetracycline is administered in the
drinking water of infected mice 337. Using this conditional expression system to generate
a transgenic parasite line in which the levels of T. gondii AMA1, expression can be
manipulated and shows that TgAMA1-depleted parasites are impaired in their ability to
attach intimately to host cells and to regulate rhoptry secretion 327, 337.
Transgenic AMA1 parasites were generated from the RH strain that is extremely
virulent with an LD100 of 1 parasite 75. When wild type mice were challenged with this
strain of parasite, they succumbed to infection with similar kinetics to RH. When
tetracycline was administered in the drinking water to mice following infection, AMA1
was repressed and there was a dramatic reduction in parasite load indicating that AMA1
is involved in parasite replication and/or host evasion in vivo.
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Materials and Methods
Culture of parasites
Wild-type RH strain T. gondii was maintained by serial passage in confluent primary
human foreskin fibroblast (HFF) cells in Dulbecco's Modified Eagle's Medium (DMEM)
supplemented 10% heat inactivated fetal bovine serum (FBS), 10 units/ml penicillin G,
10 g/ml streptomycin sulfate, and 10 mM HEPES buffer, as previously described.
TgPHIL1 parasites were generated in the Ward laboratory using the following conditions.
In order to generate the TgPhIL1 knockout construct, PCR was performed on T. gondii
genomic DNA using primers PhIL15’KOfor
(5’GCTGAGGAGGGGAAGAAGATCGAG3’) and PhIL13’KOrevXbaI
(5’TGCTCTAGATATCCGCAAATGCTCGCTCGCC3’) to generate a 6.5 kb amplicon
containing 2.9 kb of TgPhIL1 5’ flanking sequence, the 1.3 kb TgPhIL1 open reading
frame (ORF), and 3.1 kb of TgPhIL1 3’ flanking sequence. The amplified product was
cloned into pCR-Blunt TOPO (Invitrogen) and inverse PCR was performed with primers
KOinvfor (5’AGGAGTGTTCATGTTGTTTGCTG3’) and KOinvrev
(5’TGAATTCGTCTAATCCAGAGTCTGTC3’) to remove the TgPhIL1 ORF. The ble
cassette was digested from pGRA1/ble with HindIII and XbaI and the ends were filled in
with Klenow, followed by blunt ligation to the inverse PCR product in order to generate
the knockout construct p∆PhIL1/ble. The plasmid was linearized with Not1 and
transfected into RH parasites. The transfected parasites were added to confluent HFF
cells and selected with phleomycin as described previously 339. Individual clones were
isolated by limiting dilution and clones lacking TgPhIL1 expression were identified by
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immunofluorescence with anti-TgPhIL1 63. AMA1 parasites were also generated in the
Ward laboratory under the following conditions and published in 337. Briefly, The
TgAMA1 open reading frame with a C-terminal myc tag was inserted in p7TetOS1
downstream of the inducible promoter, and a chloramphenicol acetyl transferase cassette
was inserted upstream, generating p7TetOS1/AMA1-myc/CAT. Transactivatorexpressing parasites, designated here as “AMA1” parasites, were transfected with
p7TetOS1/AMA1-myc/CAT. Parasites harboring the construct were selected with
chloramphenicol and cloned by limiting dilution. Positive clones were identified by SDSPAGE/Western blotting and immunofluorescence microscopy with monoclonal
antibodies (mAbs) against TgAMA1 (B3.90,64) and against myc (9E10, Clontech). The
clone expressing the highest level of Atc-regulatable, properly localized TgAMA1-myc
(designated “AMA1/AMA1-myc”) was used to generate the TgAMA1 knockout.

Mice and infections
Female 6 to 8 week old C57BL/6 mice were obtained from Jackson Laboratories (Bar
Harbor, ME) and maintained under specific-pathogen-free conditions in accordance with
institutional guidelines. 5 mice per group were infected intraperitoneally with 200 ml of
PBS containing 104 RH or RH!TgPHIL1 tachyzoites. Peritoneal cells were harvested on
day 7 by lavage with cold PBS, spun onto coverslips and stained using the HEMA-3 kit
(Fisher Scientific) as directed by the manufacturer. Parasite DNA levels were measured
by real time PCR on DNA isolated from liver and spleen samples 7 days post-infection
using the High Pure PCR Template Purification Kit (Roche). The tandemly arrayed, 35fold-repetitive T. gondii B1 gene was amplified by real-time PCR (Forward 5’135

TCCCCTCTGCTGGCGAAAAGT-3’; Reverse 5’
AGCGTTCGTGGTCAACTATCGATTG-3’) using the AB7500 fast real-time PCR
thermal cycler and Power SYBR green reagents (Applied Biosystems, Foster City CA).
Quantitect primers for the mouse housekeeping gene β-actin (Qiagen, Valencia CA) were
used as a normalization control. The cycle numbers were normalized relative to their
individual actin signals and these were averaged among the 5 mice per group;
RHTgPHIL1 was set to 1.

Tetracycline administration
Groups of 5 C57/Bl6 mice were infected with 104 AMA1 or 2F12 parasites and either
received sterile drinking water supplemented with 0.1% sucrose (AMA1 or 2F12)
drinking water was further supplemented with 0.2 mg/ml ATc (+ATC). This water was
replenished, if exhausted, throughout the duration of the experiment.
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Results
PHIL1-knockout parasites have decreased survival and altered morphology
in vivo.
TgPHIL1-knockout parasites are outgrown by wild-type RH parasites in vitro
(Barkhuff, in press). In order to determine if there is a growth difference in vivo, mice
were infected intraperitoneally with 104 wild-type or TgPHIL1 tachyzoites. Mice
infected with either strain succumbed to infection around 7-8 days post-infection (Figure
24A). Seven days post-infection, large numbers of RH parasites were observed in the
peritoneum and significantly fewer free and intracellular parasites were detected in the
peritoneum of mice infected with the TgPHIL1 parasites (Figure 24B). The spleen and
liver were also harvested seven days after infection, and quantitative PCR (qPCR) was
performed to quantify parasite DNA. Higher concentrations of parasite DNA were
detected in the spleen and liver of mice infected with wild-type parasites than with
TgPHIL1 parasites, particularly in the spleen, where there is a four-fold decrease in
knockout parasites as compared to wild-type parasites (Figure 24C,D). These data
demonstrate that the PHIL1 knockout parasites exhibit a reduced ability to survive and/or
disseminate in mice when compared to wild-type parasites.
TgPHIL1, demonstrate an impaired ability to migrate in vitro indicating that this
PHIL1 is involved in motility and dissemination (Barkhuff, in press). PHIL1 is also a
structural protein and these knockout parasites appear misshapen when viewed by light
microscopy. To further investigate if the decreased fitness of TgPHIL1 parasites is due to
an altered morphology in vivo, RH and TgPHIL1 parasites were measured for their area
and diameter. Cytospins of peritoneal cells from day 7 infected mice were examined by
microscopy. RH-infected mice had more free tachyzoites than TgPHIL1-infected mice
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although heavily-infected cells could be visualized in these mice as well (Figure 24E).
Higher magnification of these cells indicated that these parasites had a larger, more
rounded phenotype and this was reflected in the total volume (area) and diameter of each
parasite (p<0.002, p<0.05 respectively, Figure 24 F,G). These data indicate that TgPHIL1
parasites have altered morphology in vivo and suggest that these parasites replicate and
survive less efficiently in the host
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Figure 24. TgPHIL1 parasites have decreased survival and altered morphology in
vivo. In order to determine if TgPHIL1 parasites have reduced fitness in vivo, C57/Bl6
mice (n=5) were infected with either RH or TgPHIL1 and monitored for survival or
sacrificed for parasite burdens and morphology. A) Mice succumbed to TgPHIL1
parasites with similar kinetics to RH infection. B) The number of infected cells in the
peritoneum of mice infected with TgPHIL1 was significantly lower than with RH
although this did not affect survival (p<0.01). C,D) Parasite DNA was significantly
lower in the spleen (p<0.01) of mice infected with TgPHIL1 with a similar trend toward
less parasite burden in the liver. To assess the morphology of parasites in vivo, PECs
from day 7 infected mice were cytospun onto coverslips, stained, and visualized by light
microscopy. E,F) Peritoneal cells were visualized by microscopy from day 7 infected
mice at 20X (E) and an enhanced magnification of a representative parasite. Arrows
indicate free tachyzoites in RH infected cells on the left and a representative heavilyinfected cell from the peritoneum of mice infected with TgPHIL1 (F). RH-infected mice
have more free tachyzoites and overall parasites while TgPHIL1 have fewer free
tachyzoites. G) Analysis of the diameter of each parasite as well as each parasite’s total
area was analyzed from >60 parasites from RH- and TgPHIL1-infected mice. Results are
indicative of two independent experiments. Results +/-SD.
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TgPHIL1 parasites induce similar inflammatory responses as wild-type RH
parasites
Studies from the Ward lab demonstrate that TgPHIL1 parasites possess growth
and motility defects in vitro compared to RH (Barkhuff, in press). Moreover, mice
infected with TgPHIL1 have lower parasite burdens associated with larger and more
rounded parasites than mice infected with RH. To determine if TgPHIL1 parasites
induced a stronger inflammatory response that leads to the decreased parasite burden,
sera was measured from infected mice to determine cytokine responses. Sera from mice
infected with TgPHIL1 had similar levels of IFN-γ, IL-12p40, IL-17, IL-6, and IL-10
compared to mice infected with RH (Figure 25A).

These data indicate that enhanced

pro-inflammatory cytokines are not responsible for either the reduced parasite burdens or
altered morphology of TgPHIL1 parasites. To determine if there was enhanced killing of
TgPHIL1parasites compared to RH, Immunity-related GTPases (IRG) expression was
measured. IRGs are upregulated by IFN-γ and colocalize to the parasite vacuole to
induce membrane destruction and autophagic clearance 14, 340, 341. There are multiple
proteins in mice and several of them are required for resistance including Irgm3 and Irga6
13, 153, 156

. Expression of Irgm3 and Irga6 in the spleen of TgPHIL1 parasites was

comparable to RH and Irgm3 was significantly higher in the peritoneum of TgPHIL1infected mice (p<0.05, Figure 25B,C). These data suggest a greater microbicidal activity
of inflammatory cells, presumably macrophages that more effectively destroy TgPHIL1
parasites, although this needs to be more thoroughly addressed.
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Figure 25. Mice infected with TgPHIL1 have similar immune responses compared
to mice infected with RH. TgPHIL1 have in vivo defects in replication and morphology
that may be dictated by host immune responses. In order to determine if a stronger
immune response was responsible for the decreased parasite burdens observed in
TgPHIL1-infected mice, C57/Bl6 mice were infected with RH and TgPHIL1 (n=5) and
sera was measured for cytokine production. A) IL-12p40, IFN-γ, IL-17, IL-10, and IL-6
concentrations were similar between mice infected with RH and TgPHIL1. To determine
if other markers of inflammation were enhanced in TgPHIL1-infected mice, RNA from
splenic and peritoneal cells from infected mice was analyzed for Irgm3 and Irga6
expression. B) Irgm3 expression is similar in spleen and significantly higher in the
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peritoneum of TgPHIL1-infected mice compared to RH-infected mice. C) Irga6
expression is similar in the spleen and peritoneum of RH- and TgPHIL1-infected mice.
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AMA1-deficient parasites have growth defects in vivo
AMA1 is a microneme protein that is highly conserved among Apicomplexan
parasites and is involved in parasite motility and invasion in vitro 337. To evaluate if this
protein contributes to dissemination of the parasite in vivo, a conditional deletion of
AMA1 was utilized. AMA1-deleted parasites do not grow in vitro, therefore a transgenic
parasite with a tetracycline-inducible deletion of AMA1 was utilized to measure in vivo
effects. Mice infected with either RH or the parental strain of AMA1 succumbed to
infection by day 8 post-infection (Figure 26A). Mice infected with AMA1 that were
given anhydrous tetracycline (ATC) in the drinking water survived acute challenge. The
number of infected cells in the peritoneum was significantly lower in AMA1-infected
mice as compared to RH-infected mice (p<0.01) and this was even lower in AMA1infected mice treated with ATC (Figure 26B). These data suggest that AMA1 is required
for virulence in mice as its removal dramatically reduces parasite burden.
Another clone of the AMA1 conditionally-deleted parasites, 2F12, was generated
and these two strains were compared for their ability to induce inflammatory responses
with or without the addition of ATC. AMA1 and 2F12 strains both induced strong IL12p40, IFN-γ, and IL-17 production in the sera that were similar at day 7 post-infection.
Addition of ATC to the drinking water dramatically decreased the cytokine production
for both strains although in this experiment, only 2F12 levels were statistically
significantly different (Figure 26C). These data indicate that the removal of AMA1 from
parasites affects their ability to replicate and disseminate rapidly and/or avoid the initial
immune response that can limit early parasite replication. Presumably, parasites are
killed very early following infection before a robust Th1 response can be mounted.
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Figure 26. Mice infected with conditional deletions of AMA1 have increased
survival associated with lower parasite burdens and decreased pro-inflammatory
cytokines compared to wild type parasites. AMA1 is associated with motility. To
determine if AMA1 is required for dissemination and immune evasion in vivo, C57/Bl6
mice were infected with RH and AMA1 with or without ATC. A) 5 mice per group were
infected with 103 RH or AMA1 parasites and monitored for survival. Also, ATC was
administered to the drinking water of a cohort of RH- and AMA1-infected mice starting
the day of infection. All mice infected with RH succumbed to infection by day 8 as well
145

as those infected with AMA1. Treatment of mice infected with AMA1 with ATC
rescued the mice and these mice survived for duration of the experiment (20 days). B)
The number of infected cells in the peritoneum of day 7 infected mice was measured and
there were significantly fewer parasites in in AMA1-infected mice than RH-infected mice
(p<0.01). Treatment with ATC resulted in even lower parasite burdens as well. C) 2F12
is a clone of AMA1 and both of these parasites lines were tested for their ability to elicit
pro-inflammatory cytokines. Sera from day 7 infected mice either treated with ATC or
not was measured for the presence of IL-12p40, IFN−γ, and IL-17. Both AMA1 and
2F12 induce strong production of all three of these cytokines that was not significantly
different between the strains. Addition of ATC to mice infected with either strain
dramatically reduced the production of cytokines, although these were only statistically
significant for 2F12.
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Discussion
Apicomplexans contain many subcellular structures and organelles that are
involved with parasite motility and invasion. TgPHIL1 is cytoskeleton associated,
suggesting it is involved with motility and invasion. Although deletion of TgPHIL1
during infection does not increase mouse resistance, these parasites have a large rounded
morphology, disseminate less quickly, and infected mice have lower parasite burdens in
the peritoneum and spleen. These parasites induce similar levels of pro-inflammatory
cytokines and slightly enhanced IRG expression suggesting that the latter may be
involved in early clearance of the parasites. This also suggests that the motility is linked
to virulence and the rapidity by which a parasite replicates and disseminates in vivo is a
strong indicator of success for the parasite 81.
Small growth defects are likely to present a significant selective disadvantage
over time for populations of parasites as PHIL1-deficient parasites are outcompeted by
RH parasites in vitro (Barkhuff, in press). It is surprising that such a dramatic decrease in
parasite replication and dissemination by TgPHIL1 parasites does not affect susceptibility
to the parasite. This suggests that there exists a threshold number of parasites, regardless
of strain, that determine lethality. As few as one RH parasite produces a parasite burden
sufficient to be considered uniformly lethal, while TgPHIL1 parasites produce a total
parasite burden nearly a log lower in total number of tachyzoites, but still results in death
of the host. This suggests that the rapid replication and dissemination of RH is far in
excess and evolutionarily disadvantageous to the parasite by not allowing sufficient time
to encyst in the brain and be horizontally transmitted following predation. Moreover,
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mutations in PHIL1 may have an evolutionary advantage by allowing the parasite to
persist for longer in certain hosts by limiting the speed with which the parasite replicates.
The speed of parasite replication likely directly influences parasite virulence in
terms of parasite load. Another structural protein, AMA1, is a microneme protein that
seems to be involved in parasite motility and invasion and the studies described here
suggest that the more quickly the parasite can disseminate and form cysts, the more likely
the parasite will have success 64-66. AMA1 has potential as a malaria vaccine candidate
given its proposed roles in Plasmodium dissemination 67-69, therefore a tetracylineinducible deletion of a conditional AMA1 mutant was utilized and demonstrated that
parasites depleted of AMA1 are impaired in their ability to attach to host cells and to
regulate rhoptry secretion in vitro. It was hypothesized that this in vitro defect would
translate into growth and dissemination effects in vivo thus mice were infected with
AMA1 parasites and mice were given anhydrous tetracycline to delete AMA1. These
parasites exhibited significantly lower parasite burdens associated with very minimal
cytokine production.
Since AMA1-depleted parasites are significantly impaired in rhoptry secretion,
these data support a model in which AMA1 is required for intimate attachment of the
parasite with the host cell leading to rhoptry discharge. There is also evidence provided
in Chapter III and elsewhere 307, 308, that parasites intimately attach and inject proteins
into multiple cells before invasion. This could exacerbate the AMA1 defect in motility as
the parasite, already defective in attachment, must interact not with one cell but many
cells before successfully invading a host cell and replicating. Thus, these parasites have
severely impaired invasion capabilities allowing for rapid clearance by the immune
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system. While untreated parasites replicate, although more slowly than RH, and elicit
strong pro-inflammatory responses, ATC-treated parasites are rapidly cleared from the
host suggesting that they either do not infect cells at all, may not inject their immunemodulating rhoptry proteins efficiently, and are more susceptible to anti-microbial
effector mechanisms.
These studies of two structural proteins demonstrate the necessity of the parasites to
rapidly invade a cell to avoid immune recognition. The removal of PHIL1 has prominent
effects on parasite replication and dissemination although these effects do not induce
acute resistance by the host. RH rapidly kills mice preventing its own horizontal
transmission, although this robust lethality is unlikely to occur in all species infected in
nature. However, mutations in PHIL1 could induce attenuated virulence and greater
persistence under certain circumstances. Conversely, AMA1 is required for invasion and
its removal leads to rapid recognition and destruction of the parasite before the host can
even mount a robust immune response. These studies highlight the importance of rapidly
invading host cells to avoid host resistance and how the speed and efficiency of these
early invasion events can predict parasite load and mortality.
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Chapter V.

Conclusions and future directions
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Many groups have focused on trying to better understand the basis for innate
recognition of T. gondii and how this parasite is able to manipulate host-signaling events
to promote its survival and replication. Some of the studies presented in this thesis have
addressed the influence of parasite factors that are involved in motility, invasion, and
dissemination or the ability of the host to recognize this pathogen. However, the main
finding of these studies relates to how IL-6-STAT3-SOCS3 signals impacts immune
evasion and parasite survival. These studies highlight the pleiotropic nature of IL-6 and
specifically how the cytokine is a potent inhibitor of the early production of IL-12 by
macrophages and neutrophils that is necessary to control the parasite. This work has also
built upon much of the recent literature on the interaction of T. gondii with STAT3 and
incorporated the growing understanding of how SOCS proteins regulate cytokine activity.
They advance our fundamental knowledge of STAT3 signaling events, SOCS3 and IL-6
biology, and the roles that these proteins play in determining the outcome of hostpathogen interactions.

T. gondii hijacks STAT3 signaling
In 2005, Butcher et al. demonstrated that STAT3 was required by T. gondii to
inhibit pro-inflammatory cytokine release from activated macrophages 88. This was the
first observation that a pathogen could directly induce the phosphorylation of STAT3 to
promote its own survival. This activation of STAT3 was also shown to be independent of
IL-6 and IL-10 and required for parasite-induced inhibition of IL-12 and TNF-α. This
finding was intriguing as both IL-6 and IL-10 have prominent roles during toxoplasmosis
yet were dispensable for this phenomenon 303. These observations led to the suggestion
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that T. gondii might directly phosphorylate STAT3 and a subsequent study by Saeij et.
al., reported that a parasite rhoptry protein, ROP16, was necessary for STAT3 activation
although the authors suggested that ROP16 did not act directly to phosphorylate STAT3
87

. However, subsequent studies revealed that ROP16 has kinase function and can use

STAT3 as a substrate 308, 342. Seeking to understand the molecular mechanisms behind
virulence, another report suggested a link between parasite virulence and the efficiency
with which the certain strains activated STAT3 87. Thus, less virulent type II strains had
a form of the ROP16 protein that did not activate STAT3 as efficiently as virulent type I
strains. Further support of a link to virulence was provided by data that suggested that
the pathogenicity of Type II strains could be enhanced by addition of the type I ROP16
gene that was associated with impairment of IL-12 production 87, 272. However, several
paradoxes remain. For example, the least virulent Type III strains express a version of
ROP16 that is efficient at inducing the phosphorylation of STAT3. These contradictions
and the studies discussed below on the STAT3 conditional-knockout mice suggest that
differences in parasite virulence are likely more complex than simply the strength of
STAT3 phosphorylation.

The inhibitory actions of STAT3
These studies outline the need to better understand the mechanism by which
STAT3 moderates pro-inflammatory responses. IL-6 and IL-10 utilize STAT3 to induce
the anti-inflammatory response (AIR) but exactly how STAT3 mediates inhibition of
inflammation is unclear and has been a long-standing question in the field. Many other
stimuli, in addition to the studies on T. gondii described herein, also employ STAT3152

signaling machinery to reduce inflammation and impair microbicidal function and several
proposed actions of STAT3 are described in Figure 27. Differences in STAT3
transcriptional profiles elicited by activators of the AIR may determine why certain
inhibitors of inflammation like IL-6 and IL-10 do not have identical function. IL-10 has
been shown to have strong inhibitory effects on the release of many pro-inflammatory
molecules from monocytes/macrophages such as TNF-α, IL-1b, IL-6, IL-8, IL-12, GCSF, and GM-CSF 343, 344. IL-10 also induces the release of anti-inflammatory mediators
such as the IL-1 receptor antagonist and soluble TNF-α receptors 345, 346. Furthermore, IL10 inhibits antigen presentation of monocytes and reduces surface MHC Class II and
CD86 expression 347, 348. In contrast, IL-6 is typically regarded as pro-inflammatory and
the inhibitory functions of IL-6 are less well characterized. From this study, IL-6 appears
to target the production of IL-12 and TNF-α while having no effect on NO production.
Similarly to IL-10, T. gondii inhibits many activation markers, presumably acting through
STAT3, such as NO, IL-12, IL-6, TNF-α, and MHC Class I and II 268, 349. Additionally,
T. gondii has been shown to interfere with the function of IRGs but it has not been
investigated if IL-6 and IL-10 are equally capable of interfering with IRG expression or
loading onto the parasitophorous vacuole 293, 350. There is evidence that Type I strains of
T. gondii are better at inhibiting IRG colocalization than others but it is not known if this
correlates with the strength of STAT3 phosphorylation 293. IL-10 and IL-6 have also
been implicated in interfering with the microbial killing functions of macrophages 296, 304,
351, 352

, however, the mechanisms underlying these activities are poorly understood and

have never been contrasted. Additionally, the autophagy-associated protein atg5 is linked
to parasite killing, IRG loading onto the parasitophorous vacuole, and autophagic
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Figure 27. T. gondii interferes with host-cell signaling to limit immune cell
activation and production of IL-12. 1) IL-6 and T. gondii phosphorylate STAT3
through the gp130 subunit or its secreted ROP16 protein respectively. Phosphorylated
STAT3 then travels to the nucleus. 2) T. gondii blocks phosphorylation of IFN-γactivated STAT1 or TLR-activated NF-κB (3) preventing their nuclear translocation and
upregulation of target genes. 4) Phosphorylated nuclear STAT3, often in conjunction
with NF-κB, upregulate STAT3-target genes that inhibit the production of proinflammatory genes such as IL-12 (5), induced by phosphorylated NF-κB and STAT1.
6) SOCS3 is upregulated by STAT3 but does not inhibit IL-12 production. Instead, it
acts as a negative regulator of IL-6 signaling to limit the cytokine’s ability to impair proinflammatory cytokine production.
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clearance that all are likely parts of the same mechanism. Moreover, there is a
conditional atg5 knockout with acute susceptibility to T. gondii 169 and it would be
intriguing to understand whether IL-6 or IL-10 affect this pathway.
In addition to T. gondii, other pathogens such as Epstein-Barr Virus (EBV),
Hepatitis C Virus (HCV), and Respiratory Syncitial Virus (RSV) activate STAT3 353 354,
355

. Convergence on this pathway by these different organisms suggests that STAT3

signaling is an important mediator of microbial success. However, as has been described
above, the consequence of STAT3 signals are context-dependent. For instance, the
phosphorylation of STAT3 by EBV in B cells may have entirely difference consequences
than the activation by T. gondii in macropahges. In vitro, T. gondii phosphorylates
STAT3 to limit IL-12 production from macrophages yet this ability was not shown to
have in vivo implications. Perhaps the phosphorylation of STAT3 is strongly cell typedependent; STAT3 signals in macrophages reduce pro-inflammatory cytokine production
while STAT3 phosphorylation in B cells prevents lytic viral replication and promotes
latency 356. Many of the studies on the AIR have focused on the type of STAT3 signal
provided whether it is from IL-6, IL-10, or IFN-γ and less have described the differences
in STAT3 signaling by cell type 313, 357. Thus, it may be relevant to understand that the
type of cell may be just as important for the generation of a specific AIR as the cytokine
or microbial stimulus providing it.

Macrophages do not require STAT3 for resistance to T. gondii
Given the literature that implicated STAT3 as a critical factor for parasite
virulence that inhibits the production of pro-inflammatory cytokines, it was hypothesized
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that the removal of STAT3 from macrophages would enhance cytokine production,
especially IL-12, leading to more effective control of T. gondii or perhaps the
development of immune potency. This was not observed. LysM-cre Stat3fl/fl mice did not
show enhanced resistance to more the virulent RH parasites, as these mice succumbed to
infection similarly to wild type mice. LysM-cre Stat3fl/fl mice also showed comparable
levels of IL-12 with similar survival and parasite burdens when acutely infected with Pru.
Although these mice did have lower parasite burdens chronically, this did not appear to
impact survival. These data suggest that STAT3 in macrophages is not a critical mediator
of to T. gondii.
It is possible that the lack of phenotype in LysM-cre Stat3fl/fl mice is because
macrophages and neutrophils are not the relevant cell type for T. gondii-induced STAT3
phosphorylation. Perhaps STAT3 is necessary in another cell type such as the dendritic
cell as they have been shown in other studies to be a significant source of IL-12 during
toxoplasmosis 106, 358-360. There are other data, though, that suggest that neutrophils and
macrophages are important cellular sources of IL-12 so a comparison of these LysM-cre
Stat3fl/fl mice with CD11c-cre Stat3fl/fl mice may better elucidate the contributions of
these cells to IL-12 production in vivo 361, 362. Additionally, although T. gondii can
activate STAT3 to limit pro-inflammatory responses in macrophages in vitro, the parasite
may not have the same effect in vivo. Potentially, cre-expressing parasites described in
Chapter III could be useful. For example, these parasites could be used to determine if,
following deletion of STAT3 or SOCS3 in vivo, IL-12 production was affected in certain
cell populations. These experiments could help define which populations are critical for
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IL-12 production and whether T. gondii can modify IL-12 signals in macrophages,
neutrophils, or DCs specifically, in the absence of STAT3 or SOCS3.

Differential effects of STAT3 and SOCS3 in macrophages
STAT3 is an important transcription factor that regulates many aspects of the AIR
and it has been proposed to be a critical mediator of virulence in T. gondii 86, 87, 270. It was
then hypothesized that certain proteins upregulated by the AIR downstream of STAT3
would be required for the ability of T. gondii to inhibit pro-inflammatory cytokine
production from macrophages. The first protein that was evaluated for these effects was
SOCS3 as it is aregulator of cytokine function, is downstream of STAT3 signaling, and
was upregulated following T. gondii infection 270. While LysM-cre Stat3fl/fl mice had
largely normal responses to T. gondii, LysM-cre Socs3fl/fl mice were highly susceptible.
The initial hypothesis was that STAT3 would promote T. gondii survival by upregulating
SOCS3 to limit pro-inflammatory responses. Thus, it was surprising that whereas
STAT3 had no effect on macrophages in vivo, SOCS3 was required in macrophages to
inhibit the anti-inflammatory properties of IL-6. Specifically, SOCS3 prevented IL-6
from limiting IL-12 acutely, an effect which was thought to be STAT3-mediated but
which was never tested in our studies. The phenotypes of LysM-cre Stat3fl/fl and LysMcre Socs3fl/fl mice are compared in Table 2. These data highlight the paradox that SOCS3
expression is considered to be STAT3-dependent yet LysM-cre Stat3fl/fl mice have no
phenotype while LysM-cre Socs3fl/fl mice have enhanced susceptibility. This suggests
that STAT3 is not required in macrophages for parasite control while SOCS3 is necessary
to limit IL-6 signals. Increasing this complexity, the inhibitory functions of IL-6 are
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Genotype
LysM-cre
Stat3fl/fl mice

LysM-cre
Socs3fl/fl mice

Strain

Result

RH

Mortality, D7

Pru

Resistance

ME49

Resistance

RH

Mortality, D7

Pru

Mortality,
D8-10

Notes

High, uncontrolled parasite burdens, i.p. 103
tachyzoites
Normal immune response, advances into chronic phase.
Survival past 50 days, i.p. 104 tachyzoites
Normal immune response, advances into chronic phase.
Survival past 50 days. Oral gavage 20 cysts
High, uncontrolled parasite burdens, i.p. 103
tachyzoites
High uncontrolled parasite burdens, impaired IL-12
responses, hyper IL-6 responsiveness, 104 tachyzoites

Table 2. Summary of T. gondii infections in LysM-cre Stat3fl/fl and LysM-cre Socs3fl/fl
mice. This table summarizes how LysM-cre Stat3fl/fl and LysM-cre Socs3fl/fl mice respond
to infection with various strains of T. gondii. The genotype and strain of T. gondii used
are listed in the first two columns followed by the effect this had on acute mortality.
“Resistance” is defined as the infection proceeding into the chronic phase. Mice were
sacrificed after 50 days in these cases. Notes are annotations of the systemic response of
the infection as well as the type of parasite and route of infection.
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considered to be STAT3-dependent thus it is unclear why excessive STAT3 signaling in
the macrophage is detrimental while the absence of STAT3 has no effect. One potential
explanation is that although both STAT1 and ERK signaling appeared normal in the
absence of SOCS3, these molecules have compensatory functions that mask the absence
of STAT3 in macrophages and are required for these effects in vivo. Another suggestion
is that in vivo, IL-6 does not need STAT3 to limit inflammation in macrophages as long
as it can suppress IL-12 in other cell types, i.e. DCs. DCs are a prominent cell type for
IL-12 production, therefore CD11c-cre Socs3fl/fl mice should exhibit a similar phenotype
to LysM-cre Socs3fl/fl mice as the initial burst of IL-12 is important, regardless of cell type
106, 363-365

. If CD11c-cre Socs3fl/fl mice are resistant to T. gondii, it would suggest that

macrophages and/or neutrophils play a more important role in early IL-12 production and
this is an ongoing debate in the scientific community. It would also be interesting to
know if IL-6 can antagonize IL-12 production from DCs or if these effects are cellspecific and more importantly to determine if the quality or type of AIR induced by T.
gondii, IL-10, and IL-6 is dependent upon cell type and these effects could be contrasted
by taking a genomic microarray approach to measure broad transcriptional regulation

Functions of SOCS3 in the immune system
Presently, there is limited understanding of SOCS3 biology as it relates to
immunity to infection and many of the proposed functions are highlighted in Figure 28.
IL-6 has been shown to signal through the gp130 receptor and these events can be
inhibited by SOCS3 binding to gp130 and inhibiting access of STATs and JAKs to the
docking site on the receptor 252. SOCS3 is not constitutively expressed but associates with
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Figure 28. Proposed intracellular functions of SOCS3. 1) STAT3 is phosphorylated
directly by T. gondii through the secreted kinase ROP16. 2) Phosphorylated STAT3
enters the nucleus and upregulates STAT3-dependent genes, some of which are involved
in turning off IL-12 production. 3) SOCS3 acts to turn off gp130 signaling by binding to
Y757 on the gp130 subunit. This is thought to sterically inhibit STAT3 docking to the
receptor. 4) Additionally, SOCS3 impairs ROP16-mediated phosphorylation of STAT3
although this mechanism is unclear. Possible inhibitory functions for SOCS3 are the
direct binding and inhibition of STAT3 or its upstream kinases or polyubiquitination and
proteasomal degradation of STAT3 (5), ROP16, gp130, or any other proteins involved in
this cascade.

160

surface-bound receptors following its upregulation by various stimuli such as IL-6 and
IFN-γ 252. Its SOCS box, a C-terminal domain with strong homology among SOCS
proteins, is capable of recruiting E3 ubiquitin ligases domain and binds to elongin BC
and cullin5, yet direct substrates have yet to be identified 366. The presence of the SOCS
box suggests that SOCS3 regulates cytokines through ubiquitination and proteasomal
degradation of various intermediate proteins such as JAKs, Tyk2, STATs themselves, or
other related substrates and kinases although there is currently little experimental
evidence to support this conclusion 257, 258, 367-369.
It has previously been appreciated that SOCS3 is a negative regulator of IL-6 and
other cytokines such as IL-27, LIF, and IL-11 that signal through the gp130 receptor,
however no prominent role for this protein during infection had been described 254, 267, 305,
370, 371

. Nevertheless, SOCS3 is upregulated in cells infected with a variety of pathogens

including Leishmania, Mycobacterium, and T. gondii 372, 373. Although SOCS3 function
has not been well characterized during infection in vivo, a vital role for the protein during
development has been identified as SOCS3 deletions in mice lead to impaired
erythropoiesis and embryonic lethality 374. Therefore, it was difficult to utilize SOCS3knockout mice so a conditional deletion of SOCS3 in macrophage and neutrophil
lineages, LysM-cre Socs3fl/fl was used for infections.
LysM-cre Socs3fl/fl mice succumb to infection with T. gondii by 10 days post
infection associated with defects in IL-12 production that are mediated by IL-6 signaling.
Traditionally, IL-6 has been regarded as pro-inflammatory in many experimental settings
and IL-6-deficient animals succumb to infection with T. gondii during the chronic phase
of infection associated with a defect in humoral immunity and enhanced parasite burdens
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(Silver et al., unpublished material) 179. While the data described here do not address how
SOCS3 specifically inhibits IL-6 signaling, studies using a gp130 hypermorph, mice with
a mutation in gp130 that prevents SOCS3 binding, are helpful. In these mice, the failure
of SOCS3 to bind gp130 results in exaggerated STAT3 signaling and these mice
succumb to T. gondii infection with impaired IL-12 production similar to LysM-cre
Socs3fl/fl mice 375. Combined, these studies demonstrate the requirement for innate cell
expression of SOCS3 to limit the potentially damaging inhibitory functions of IL-6.
Somewhat surprising, treatment of chronically-infected mice with neutralizing antibodies
to IL-6 results in enhanced microbicidal killing associated with decreased inflammation
and reduced parasite burdens suggesting that IL-6 promotes chronic parasite growth 180.
IL-10, which also signals primarily through STAT3, is required during the acute phase of
infection, with IL-10-knockout mice succumbing to infection within the first two weeks
due to an unchecked inflammatory response and severe immune-mediated pathology 376.
This effect is not observed in IL-6-deficient mice despite the strong inhibitory effects
presumably because of the presence of strong IL-10 responses and that fact that IL-6 does
have anti-parasitic functions that are required for chronic immunity (Silver, unpublished
data) 180.
One unexpected result, described in Chapter 3, was that T. gondii induced
stronger phosphorylation of STAT3 in SOCS3-deficient macrophages. SOCS3 is
considered to inhibit only gp130-mediated STAT3 signals, i.e. it does not inhibit IL-10induced pSTAT3. Since ROP16 has not been described to interact with gp130, it is
surprising that the absence of SOCS3 would affect ROP16-mediated phosphorylation of
STAT3. The question of why T. gondii induces stronger phosphorylation of STAT3 in
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the absence of SOCS3 is an interesting one. Some suggested mechanisms are shown in
Figure 28. Given the E3 ubiquitin ligase-recruiting properties of SOCS3, it is possible
that SOCS3 induces degradation of ROP16, STAT3, or another protein that interacts with
these proteins. SOCS3 may also recruit phosphatases, such as SH2-domain-containing
protein-tyrosine phosphatase (SHP)-1, that diminish overall STAT3 phosphorylation and
additional studies will be required to determine if any of these proposed functions are
relevant during T. gondii infection.

Final Comments
Together, the studies presented here outline a fundamental model of hostpathogen interactions and how one evolves strategies to limit the functions of the other.
T. gondii, and pathogens in general, have evolved a number of mechanisms to undermine
host-cell signaling to promote pathogen replication, survival, dissemination, and
transmission. This thesis has discussed how T. gondii uses STAT3 to diminish
macrophage production of pro-inflammatory cytokines and how the macrophage
upregulates SOCS3 to limit excessive STAT3 signaling. This thesis has also described
how inflammatory responses need to be tightly regulated to avoid excessive inflammation
and how these anti-inflammatory responses can be usurped by pathogens to enhance their
own success. Some of the more interesting data to come from these studies was the
comparison between mice with STAT3- and SOCS3-deficient macrophages. Initially
thought to be intimately associated with each other, the dramatic difference in phenotype
between LysM-cre Stat3fl/fl and LysM-cre Socs3fl/fl mice is puzzling. This suggests a
complexity in STAT3 and SOCS3 signaling that was previously unappreciated and may
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depend on cell type and timing of these signals. It is also curious to know if either
STAT3 or SOCS3 have different functions in T cells or DCs and whether comparisons
with targeted deletions of these proteins in those populations can help us better
understand how cytokines such as IL-6 and IL-10 function in vivo during T. gondii
infection.
This thesis began by evaluating whether different strains of T. gondii have unique
effects on host-signaling. Despite prior literature to the contrary, the data described in
this thesis suggest that T. gondii-induced STAT3 may not be different between strains
and that the differences observed in virulence are more complex with multiple inducers
of STAT3 having variable effects in different cell types. These studies highlight the
utility of targeting SOCS3 and STAT3 for use in therapeutic settings to limit
inflammation and also support the use of blocking IL-6 for treatment of certain infections
such as T. gondii and L. major. There are a number of possible ways to specifically
target these genes but these effects will be different depending on the context of the
inflammation or pathogen. Inhibition of STAT3 signals could be achieved by smallmolecule inhibitors of activation, but these efforts would need to be targeted to certain
cells types creating difficulties. Potential therapies for decreasing STAT3 signals could
be the amelioration of pathogen-induced disease or for enhanced production of IL-12 in
settings where this cytokine is lacking. The same could be said for SOCS3 where the
ability to specifically impair IL-6 activity could be somehow inflammation in arthritis, or
IL-6-mediated inhibition of IL-12 for certain intracellular pathogens such as T. gondii.
IL-6 is often found upregulated in hyper-inflammatory and autoimmune diseases such as
multiple sclerosis, arthritis, and Crohn’s Disease. While blocking IL-6 with the
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neutralizing antibody tocilizumab has the potential to be used in any condition with
enhanced IL-6, targeting SOCS3 specifically may have similar effects with less adverse
effects. Targeting SOCS3 or using tocilizumab during acute infections or recurring
infections such as chronic TE in HIV/AIDS patients may also limit sequelae and control
parasite burdens although side effects such as respiratory tract infections, headaches,
hypertension (high blood pressure), and liver injury have been reported 377, 378. As
STAT3 is activated in a variety of inflammatory, developmental, and infectious
situations, the utility of affecting the phosphorylation or expression of STAT3 must be
carefully weighed to specifically target desired pathways and prevent unwanted
consequences.
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VI.

Appendix
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During the course of these experiments, many different avenues of research were
broached but not carried out in any full detail. Some of these are included here such that
there may be record should future researchers endeavor to follow up on them.
The following are experiments very similar to those outlined in this dissertation.
They are all LPS inhibition assays and the methods for each are discussed in the Methods
sections in both Chapters II and III. Briefly, BMMφ were infected with RH or Pru or
given STAg for 1 hr followed by LPS stimulation for 24 hrs. ELISAs were performed on
supernatants. Bone-marrow was taken from various knockout mice, generously donated
to the lab from various places over the years. Many are commercially available.
Cryopyrin, NALP12, IPAF, and ASC are all proteins involved in the inflammasome
complex and are reviewed in detail in 379. It was hypothesized that some of these
molecules might be involved in innate recognition of T. gondii and/or might be
responsible for the parasite’s ability to restrict pro-inflammatory responses from activated
macrophages. Reports from this lab and others demonstrate cRel’s importance in IL-12
production 99. Many of these panels are incomplete or negative and their inclusion in this
dissertation is to provide suggestions for future research.
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Appendix A-D. Nalp12 and Cryopyrin are dispensable for RH-mediated inhibition
of LPS-induced cytokine production. IL-12p40, nitrite, IL-6, and IL-10 were measured
from macrophages pre-incubated with RH or STAg before LPS stimulation. Nalp12- and
Cyropyrin-deficient macrophages show the same phenotype for IL-12p40 and nitrite
inhibition by RH. IL-6 results are varied. Curiously, Nalp12-deficient macrophages
show significantly greater IL-12p40 and IL-10 production than wild type macrophages
suggesting that Nalp12 is an inhibitor of IL-12 and IL-10.

Appendix E,F. Ipaf- and ASC-deficient macrophages are similar to wild type
macrophages in cytokine production and play no role in T. gondii-mediate inhibition
of pro-inflammatory responses. TNF-α and nitrite were measured from macrophages
pre-incubated with RH or Pru or given STAg before LPS stimulation. Results are
indicative of experiments described in this dissertation and Ipaf- and ASC-knockout
macrophages resemble wild type macrophages for both pro-inflammatory molecules.

Appendix G. cRel-deficient macrophages produce lower concentrations of IL-12p40
following LPS stimulation. IL-12p40 was measured from wild type and cRel-deficient
macrophages pre-incubated with RH or Pru or given STAg before LPS stimulation.
Overall IL-12p40 production was significantly lower in cRel-/- macrophages than control
macrophages as expected. RH was still able to reduce further the IL-12p40 that cRel-/macrophages could produce suggesting that this protein is not required for this
phenomenon.
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